日本臨牀　82/増刊5　動脈・静脈の疾患2024（下）

出版社： 日本臨牀社
発行日： 2024-07-31
分野： 臨床医学：一般  >  雑誌
ISSN： 00471852
雑誌名：
特集： 動脈・静脈の疾患2024（下）
電子書籍版： 2024-07-31 （初版第1刷）
書籍・雑誌
≪全国送料無料でお届け≫
取寄せ目安：4～8営業日

22,000 円(税込)

購入する
電子書籍
章別単位での購入はできません
ブラウザ、アプリ閲覧

22,000 円(税込)

購入する

目次

  • 特集　動脈・静脈の疾患2024（下）
    　　　―最新の診断・治療動向―

    序文

    IV 動脈・静脈の疾患(臓器別)
    　1．虚血性心疾患
    　　(1) 病因と病態
    　　(2) 診断
    　　(3) 内科治療(経皮的冠動脈インターベンション，薬物療法)
    　　(4) 外科治療
    　2．脳血管疾患
    　　(1) 脳梗塞
    　　　1) 病因と病態
    　　　2) 診断
    　　　3) 脳梗塞に対する内科治療：最新の知見と今後の展望
    　　　4) 外科治療
    　　(2) 一過性脳虚血発作
    　　(3) 脳出血
    　　　1) 脳出血の病因と病態
    　　　2) 脳出血の診断
    　　　3) 治療
    　　(4) くも膜下出血
    　　　1) 病因と病態
    　　　2) 診断
    　　　3) くも膜下出血の治療における最近のトピック
    　　(5) 脳静脈洞血栓症
    　　(6) もやもや病
    　3．肺血管疾患
    　　(1) 急性肺血栓塞栓症
    　　　1) 病因と病態
    　　　2) 急性肺血栓塞栓症の診断
    　　　3) 治療
    　　(2) 慢性肺血栓塞栓症
    　　　1) 病因と病態
    　　　2) 診断
    　　　3) 治療
    　　(3) 肺高血圧症
    　　　1) 肺高血圧症病因と病態
    　　　2) 診断
    　　　3) 治療
    　4．消化管疾患
    　　(1) 胃前庭部毛細血管拡張症
    　　(2) 遺伝性出血性末梢血管拡張症
    　　(3) Dieulafoy 潰瘍・病変
    　　(4) 胃動静脈奇形，血管腫
    　　(5) 腸間膜動脈閉塞症
    　　(6) 腸間膜静脈硬化症
    　　(7) 食道胃静脈瘤
    　　(8) 痔核
    　5．腎臓疾患
    　　(1) 腎動脈狭窄症
    　　(2) 腎梗塞
    　　(3) 腎動脈瘤
    　　(4) コレステロール塞栓症の病態と治療
    　　(5) 腎静脈血栓症
    V 血管炎
    　1．分類
    　2．大型血管炎
    　　(1) 高安動脈炎
    　　(2) 巨細胞性動脈炎
    　3．中型血管炎
    　　(1) 結節性多発動脈炎
    　　(2) 川崎病の最新の診断・治療動向
    　4．小型血管炎
    　　(1) ANCA 関連血管炎
    　　　1) 顕微鏡的多発血管炎の最新知見と治療戦略
    　　　2) 多発血管炎性肉芽腫症
    　　　3) 好酸球性多発血管炎性肉芽腫症
    　　(2) 免疫複合体性血管炎
    　　　1) 抗GBM 病
    　　　2) クリオグロブリン血症性血管炎
    　　　3) IgA 血管炎の診断と治療
    　5．多彩な血管を侵襲する血管炎
    　　(1) 血管ベーチェット病
    　　(2) コーガン症候群
    　6．単一臓器血管炎
    　7．全身性疾患関連血管炎
    　　(1) 全身性エリテマトーデス(SLE)に伴う血管炎
    　　(2) リウマトイド血管炎・悪性関節リウマチ
    　　(3) サルコイド血管炎

この書籍の参考文献

参考文献のリンクは、リンク先の都合等により正しく表示されない場合がありますので、あらかじめご了承下さい。

本参考文献は電子書籍掲載内容を元にしております。

IV 動脈・静脈の疾患 ( 臓器別 )

P.12 掲載の参考文献
1) Khera AV, Emdin CA, Drake I, et al : Genetic Risk, Adherence to a Healthy Lifestyle, and Coronary Disease. N Engl J Med 375 : 2349-2358, 2016.
 
2) Libby P : Current concepts of the pathogenesis of the acute coronary syndromes. Circulation 104 : 365-372, 2001.
PubMed
3) Knuuti J, Wijns W, Saraste A, et al : 2019 ESC Guidelines for the diagnosis and management of chronic coronary syndromes. Eur Heart J 41 : 407-477, 2020.
PubMed
4) Beltrame JF : Assessing patients with myocardial infarction and nonobstructed coronary arteries (MINOCA). J Intern Med 273 : 182-185, 2013.
PubMed
5) Bairey Merz CN, Pepine CJ, Walsh MN, et al : Ischemia and No Obstructive Coronary Artery Disease (INOCA) : Developing Evidence-Based Therapies and Research Agenda for the Next Decade. Circulation 135 : 1075-1092, 2017.
PubMed
6) 2023年JCS/CVIT/JCCガイドライン フォーカスアップデート版 冠攣縮性狭心症と冠微小循環障害の診断と治療, 2023. [https://www.j-circ.or.jp/cms/wp-content/uploads/2023/03/JCS2023_hokimoto.pdf] (2024年7月閲覧)
 
P.20 掲載の参考文献
1) Knuuti J, Wijns W, Saraste A, et al : 2019 ESC Guidelines for the diagnosis and management of chronic coronary syndromes. Eur Heart J 41 : 407-477, 2020.
PubMed
2) 日本循環器学会 : 2022年JCSガイドラインフォーカス アップデート版 安定冠動脈疾患の診断と治療, 2022.
 
3) 日本循環器学会 : 急性冠症候群ガイドライン (2018年改訂版), 2019.
 
4) Ibanez B, James S, Agewall S, et al : 2017 ESC Guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevation : The Task Force for the management of acute myocardial infarction in patients presenting with ST-segment elevation of the European Society of Cardiology (ESC). Eur Heart J 39 : 119-177, 2018.
 
5) Kosuge M, Kimura K, Ishikawa T, et al : Differences between men and women in terms of clinical features of ST-segment elevation acute myocardial infarction. Circ J 70 : 222-226, 2006.
 
6) Rokos IC, French WJ, Koenig WJ, et al : Integration of pre-hospital electrocardiograms and ST-elevation myocardial infarction receiving center (SRC) networks : impact on Door-to-Balloon times across 10 independent regions. JACC Cardiovasc Interv 2 : 339-346, 2009.
 
7) Granger CB, Goldberg RJ, Dabbous O, et al : Predictors of hospital mortality in the global registry of acute coronary events. Arch Intern Med 163 : 2345-2353, 2003.
PubMed
8) Eagle KA, Lim MJ, Dabbous OH, et al : A validated prediction model for all forms of acute coronary syndrome : estimating the risk of 6-month postdischarge death in an international registry. JAMA 291 : 2727-2733, 2004.
 
9) Fox KA, Dabbous OH, Goldberg RJ, et al : Prediction of risk of death and myocardial infarction in the six months after presentation with acute coronary syndrome : prospective multinational observational study (GRACE). BMJ 333 : 1091, 2006.
 
10) Knuuti J, Wijns W, Saraste A, et al : 2019 ESC Guidelines for the diagnosis and management of chronic coronary syndromes. Eur Heart J 41 : 407-477, 2020.
PubMed
11) Winther S, Schmidt SE, Mayrhofer T, et al : Incorporating Coronary Calcification Into Pre-Test Assessment of the Likelihood of Coronary Artery Disease. J Am Coll Cardiol 76 : 2421-2432, 2020.
PubMed
12) Shaw LJ, Berman DS, Picard MH, et al : Comparative definitions for moderate-severe ischemia in stress nuclear, echocardiography, and magnetic resonance imaging. JACC Cardiovasc Imaging 7 : 593-604, 2014.
 
13) Bangalore S, Maron DJ, O'Brien SM, et al : Management of Coronary Disease in Patients with Advanced Kidney Disease. N Engl J Med 382 : 1608-1618, 2020.
 
14) Maron DJ, Hochman JS, Reynolds HR, et al : Initial Invasive or Conservative Strategy for Stable Coronary Disease. N Engl J Med 382 : 1395-1407, 2020.
 
15) 日本循環器学会, 日本心血管インターベンション治療学会, 日本心臓病学会 : 2023年JCS/CVIT/JCCガイドラインフォーカス アップデート版 冠攣縮性狭心症と冠微小循環障害の診断と治療, 2023.
 
P.26 掲載の参考文献
1) Nakamura M, Yaku H, Ako J, et al : JCS/JSCVS 2018 Guideline on Revascularization of Stable Coronary Artery Disease. Circ J 86 : 477-588, 2022.
PubMed
2) Sakakura K, Jinnouchi H, Taniguchi Y, et al : Lifetime management of severely calcified coronary lesions : the treatment algorithm focused on the shape of calcification. Cardiovasc Interv Ther 38 : 375-380, 2023.
 
3) Stone GW, Christiansen EH, Ali ZA, et al : Intravascular imaging-guided coronary drug-eluting stent implantation : an updated network meta-analysis. Lancet 403 : 824-837, 2024.
 
4) Lee JM, Choi KH, Song YB, et al : Intravascular Imaging-Guided or Angiography-Guided Complex PCI. N Engl J Med 388 : 1668-1679, 2023.
 
5) Kimura K, Kimura T, Ishihara M, et al : JCS 2018 Guideline on Diagnosis and Treatment of Acute Coronary Syndrome. Circ J 83 : 1085-1196, 2019.
PubMed
6) Maron DJ, Hochman JS, Reynolds HR, et al : Initial Invasive or Conservative Strategy for Stable Coronary Disease. N Engl J Med 382 : 1395-1407, 2020.
 
7) Perera D, Clayton T, O'Kane PD, et al : Percutaneous Revascularization for Ischemic Left Ventricular Dysfunction. N Engl J Med 387 : 1351-1360, 2022.
 
8) Nakano S, Kohsaka S, Chikamori T, et al : JCS 2022 Guideline Focused Update on Diagnosis and Treatment in Patients With Stable Coronary Artery Disease. Circ J 86 : 882-915, 2022.
PubMed
9) Watanabe H, Domei T, Morimoto T, et al : Effect of 1-Month Dual Antiplatelet Therapy Followed by Clopidogrel vs 12-Month Dual Antiplatelet Therapy on Cardiovascular and Bleeding Events in Patients Receiving PCI : The STOPDAPT-2 Randomized Clinical Trial. JAMA 321 : 2414-2427, 2019.
 
10) Nakamura M, Kimura K, Kimura T, et al : JCS 2020 Guideline Focused Update on Antithrombotic Therapy in Patients With Coronary Artery Disease. Circ J 84 : 831-865, 2020.
PubMed
11) Wang N, Fulcher J, Abeysuriya N, et al : Intensive LDL cholesterol-lowering treatment beyond current recommendations for the prevention of major vascular events : a systematic review and meta-analysis of randomised trials including 327 037 participants. Lancet Diabetes Endocrinol 8 : 36-49, 2020.
 
12) Okamura T, Tsukamoto K, Arai H, et al : Japan Atherosclerosis Society (JAS) Guidelines for Prevention of Atherosclerotic Cardiovascular Diseases 2022. J Atheroscler Thromb 31 : 641-853, 2024.
 
13) Mach F, Baigent C, Catapano AL, et al : 2019 ESC/EAS Guidelines for the management of dyslipidaemias : lipid modification to reduce cardiovascular risk. Eur Heart J 41 : 111-188, 2020.
PubMed
14) Mitani H, Suzuki K, Ako J, et al : Achievement Rates for Low-Density Lipoprotein Cholesterol Goals in Patients at High Risk of Atherosclerotic Cardiovascular Disease in a Real-World Setting in Japan. J Atheroscler Thromb 30 : 1622-1634, 2023.
 
P.32 掲載の参考文献
1) Byrne RA, Rossello X, Coughlan JJ, et al : 2023 ESC Guidelines for the management of acute coronary syndromes. Eur Heart J 44 : 3720-3826, 2023.
 
2) Kimura K, Kimura T, Ishihara M, et al : JCS 2018 Guideline on Diagnosis and Treatment of Acute Coronary Syndrome. Circ J 83 : 1085-1196, 2019.
PubMed
3) Lawton JS, Tamis-Holland JE, Bangalore S, et al : 2021 ACC/AHA/SCAI Guideline for Coronary Artery Revascularization : A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines. Circulation 145 : e18-e114, 2022.
 
4) Collet JP, Thiele H, Barbato E, et al : 2020 ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation. Eur Heart J 42 : 1289-1367, 2021.
PubMed
5) Nakamura M, Yaku H, Ako J, et al : JCS/JSCVS 2018 Guideline on Revascularization of Stable Coronary Artery Disease. Circ J 86 : 477-588, 2022.
PubMed
6) Fearon WF, Zimmermann FM, De Bruyne B, et al : Fractional Flow Reserve-Guided PCI as Compared with Coronary Bypass Surgery. N Engl J Med 386 : 128-137, 2022.
 
7) Zimmermann FM, Ding VY, Pijls NHJ, et al : Fractional Flow Reserve-Guided PCI or Coronary Bypass Surgery for 3-Vessel Coronary Artery Disease : 3-Year Follow-Up of the FAME 3 Trial. Circulation 148 : 950-958, 2023.
 
8) Nakano S, Kohsaka S, Chikamori T, et al : JCS 2022 Guideline Focused Update on Diagnosis and Treatment in Patients With Stable Coronary Artery Disease. Circ J 86 : 882-915, 2022.
PubMed
9) Maron DJ, Hochman JS, Reynolds HR, et al : Initial Invasive or Conservative Strategy for Stable Coronary Disease. N Engl J Med 382 : 1395-1407, 2020.
 
10) Sabik JF 3rd, Mehaffey JH, Badhwar V, et al : Multiarterial vs Single-Arterial Coronary Surgery : 10-Year Follow-up of 1 Million Patients. Ann Thorac Surg 117 : 780-788, 2024.
 
11) Taggart DP, Audisio K, Gerry S, et al : Single versus multiple arterial grafting in diabetic patients at 10 years : the Arterial Revascularization Trial. Eur Heart J 43 : 4644-4652, 2022.
 
12) Puskas JD, Halkos ME, DeRose JJ, et al : Hybrid Coronary Revascularization for the Treatment of Multivessel Coronary Artery Disease : A Multicenter Observational Study. J Am Coll Cardiol 68 : 356-365, 2016.
 
13) Esteves V, Oliveira MAP, Feitosa FS, et al : Late clinical outcomes of myocardial hybrid revascularization versus coronary artery bypass grafting for complex triple-vessel disease : Long-term follow-up of the randomized MERGING clinical trial. Catheter Cardiovasc Interv 97 : 259-264, 2021.
 
14) Tsutsui H, Isobe M, Ito H, et al : JCS 2017/JHFS 2017 Guideline on Diagnosis and Treatment of Acute and Chronic Heart Failure-Digest Version. Circ J 83 : 2084-2184, 2019.
PubMed
15) Tsutsui H, Ide T, Ito H, et al : JCS/JHFS 2021 Guideline Focused Update on Diagnosis and Treatment of Acute and Chronic Heart Failure. Circ J 85 : 2252-2291, 2021.
 
P.38 掲載の参考文献
1) Sacco RL, Kasner SE, Broderick JP, et al : An updated definition of stroke for the 21st century : a statement for healthcare professionals from the American Heart Association/American Stroke Association. Stroke 44 : 2064-2089, 2013.
 
2) Special report from the National Institute of Neurological Disorders and Stroke. Classification of cerebrovascular diseases III. Stroke 21 : 637-676, 1990.
PubMed
3) Adams HP Jr, Bendixen BH, Kappelle LJ, et al : Classification of subtype of acute ischemic stroke. Definitions for use in a multicenter clinical trial. TOAST. Trial of Org 10172 in Acute Stroke Treatment. Stroke 24 : 35-41, 1993.
 
4) Regenhardt RW, Das AS, Lo EH, et al : Advances in Understanding the Pathophysiology of Lacunar Stroke : A Review. JAMA Neurol 75 : 1273-1281, 2018.
 
5) Wardlaw JM, Smith EE, Biessels GJ, et al : Neuroimaging standards for research into small vessel disease and its contribution to ageing and neurodegeneration. Lancet Neurol 12 : 822-838, 2013.
 
6) Ringelstein EB, Zeumer H, Angelou D : The pathogenesis of strokes from internal carotid artery occlusion. Diagnostic and therapeutical implications. Stroke 14 : 867-875, 1983.
 
7) Caplan LR, Wong KS, Gao S, et al : Is hypoperfusion an important cause of strokes? If so, how? Cerebrovasc Dis 21 : 145-153, 2006.
 
8) Yong SW, Bang OY, Lee PH, et al : Internal and cortical border-zone infarction : clinical and diffusion-weighted imaging features. Stroke 37 : 841-846, 2006.
 
9) 松岡秀樹 : 3. 脳動脈解離の現状 (2) 本邦の実態 (アンケート調査, 後ろ向き登録研究から). 脳動脈解離診療の手引き (峰松一夫, 松岡秀樹, 徳永梓, ほか編), p8-16, 国立循環器病センター内科脳血管部門, 2009.
 
10) Viedma-Guiard E, Guidoux C, Amarenco P, et al : Aortic Sources of Embolism. Front Neurol 11 : 606663, 2020.
 
11) Yasaka M, Otsubo R, Oe H, et al : Is stroke a paradoxical embolism in patients with patent foramen ovale? Intern Med 44 : 434-438, 2005.
PubMed
12) Saver JL, Mattle HP, Thaler D : Patent Foramen Ovale Closure Versus Medical Therapy for Cryptogenic Ischemic Stroke : A Topical Review. Stroke 49 : 1541-1548, 2018.
 
13) Tsivgoulis G, Katsanos AH, Kohrmann M, et al : Embolic strokes of undetermined source : theoretical construct or useful clinical tool? Ther Adv Neurol Disord 12 : 1756286419851381, 2019.
 
14) Kamel H, Merkler AE, Iadecola C, et al : Tailoring the Approach to Embolic Stroke of Undetermined Source : A Review. JAMA Neurol 76 : 855-861, 2019.
 
15) Sanna T, Diener HC, Passman RS, et al : Cryptogenic stroke and underlying atrial fibrillation. N Engl J Med 370 : 2478-2486, 2014.
 
P.45 掲載の参考文献
1) 必携 脳卒中ハンドブック [改訂第4版] (高嶋修太郎, 伊藤義彰編), 診断と治療社, 2024.
 
P.50 掲載の参考文献
1) 厚生労働省 : 令和元年 (2019) 人口動態統計月報年計 (概数) の概況, 2020.
 
2) Toyoda K : Epidemiology and registry studies of stroke in Japan. J Stroke 15 : 21-26, 2013.
 
3) 脳卒中治療ガイドライン 2021 [改訂2023] (日本脳卒中学会脳卒中ガイドライン委員会編), 協和企画, 2023.
 
4) Powers WJ, Rabinstein AA, Ackerson T, et al : Guidelines for the Early Management of Patients With Acute Ischemic Stroke : 2019 Update to the 2018 Guidelines for the Early Management of Acute Ischemic Stroke : A Guideline for Healthcare Professionals From the American Heart Association/American Stroke Association. Stroke 50 : e344-e418, 2019.
 
5) 日本脳卒中学会脳卒中医療向上・社会保険委員会静注血栓溶解療法指針改訂部会 : 静注血栓溶解 (rt-PA) 療法適正治療指針 第三版. 脳卒中 41 : 205-246, 2019.
 
6) Emberson J, Lees KR, Lyden P, et al : Effect of treatment delay, age, and stroke severity on the effects of intravenous thrombolysis with alteplase for acute ischaemic stroke : a meta-analysis of individual patient data from randomised trials. Lancet 384 : 1929-1935, 2014.
 
7) Campbell BCV, Ma H, Ringleb PA, et al : Extending thrombolysis to 4.5-9 h and wake-up stroke using perfusion imaging : a systematic review and meta-analysis of individual patient data. Lancet 394 : 139-147, 2019.
 
8) Kawano H, Hirano T, Inoue M, et al : Tenecteplase versus alteplase for large vessel occlusion recanalization (T-FLAVOR) : Trial protocol. Eur Stroke J 7 : 71-75, 2022.
 
9) Wang Y, Pan Y, Zhao X, et al : Clopidogrel With Aspirin in Acute Minor Stroke or Transient Ischemic Attack (CHANCE) Trial : One-Year Outcomes. Circulation 132 : 40-46, 2015.
 
10) Johnston SC, Easton JD, Farrant M, et al : Clopidogrel and Aspirin in Acute Ischemic Stroke and High-Risk TIA. N Engl J Med 379 : 215-225, 2018.
 
11) Shinohara Y, Katayama Y, Uchiyama S, et al : Cilostazol for prevention of secondary stroke (CSPS 2) : an aspirin-controlled, double-blind, randomised non-inferiority trial. Lancet Neurol 9 : 959-968, 2010.
 
12) Kimura S, Toyoda K, Yoshimura S, et al : Practical "1-2-3-4-Day" Rule for Starting Direct Oral Anticoagulants After Ischemic Stroke With Atrial Fibrillation : Combined Hospital-Based Cohort Study. Stroke 53 : 1540-1549, 2022.
 
13) Oldgren J, Asberg S, Hijazi Z, et al : Early Versus Delayed Non -Vitamin K Antagonist Oral Anticoagulant Therapy After Acute Ischemic Stroke in Atrial Fibrillation (TIMING) : A Registry-Based Randomized Controlled Noninferiority Study. Circulation 146 : 1056-1066, 2022.
 
14) Fischer U, Koga M, Strbian D, et al : Early versus Later Anticoagulation for Stroke with Atrial Fibrillation. N Engl J Med 388 : 2411-2421, 2023.
 
15) Ruff CT, Giugliano RP, Braunwald E, et al : Comparison of the efficacy and safety of new oral anticoagulants with warfarin in patients with atrial fibrillation : a meta-analysis of randomised trials. Lancet 383 : 955-962, 2014.
 
16) Koga M, Toyoda K, Minematsu K, et al : Long-Term Effect of Pravastatin on Carotid Intima-Media Complex Thickness : The J-STARS Echo Study (Japan Statin Treatment Against Recurrent Stroke). Stroke 49 : 107-113, 2018.
 
P.57 掲載の参考文献
1) Goyal M, Menon BK, van Zwam WH, et al : Endovascular thrombectomy after large-vessel ischaemic stroke : a meta-analysis of individual patient data from five randomised trials. Lancet 387 : 1723-1731, 2016.
 
2) 日本脳卒中学会, 日本脳神経外科学会, 日本脳神経血管内治療学会 : 経皮経管的脳血栓回収用機器適正使用指針 [第5版], 2023.
 
3) 脳卒中治療ガイドライン 2021 [改訂2023] (日本脳卒中学会脳卒中ガイドライン委員会編), 協和企画, 2023.
 
4) Nogueira RG, Jadhav AP, Haussen DC, et al : Thrombectomy 6 to 24 Hours after Stroke with a Mismatch between Deficit and Infarct. N Engl J Med 378 : 11-21, 2018.
 
5) Albers GW, Marks MP, Kemp S, et al : Thrombectomy for Stroke at 6 to 16 Hours with Selection by Perfusion Imaging. N Engl J Med 378 : 708-718, 2018.
 
6) Yoshimura S, Sakai N, Yamagami H, et al : Endovascular Therapy for Acute Stroke with a Large Ischemic Region. N Engl J Med 386 : 1303-1313, 2022.
 
7) Goyal N, Tsivgoulis G, Malhotra K, et al : Medical Management vs Mechanical Thrombectomy for Mild Strokes : An International Multicenter Study and Systematic Review and Meta-analysis. JAMA Neurol 77 : 16-24, 2020.
 
8) Menon BK, Hill MD, Davalos A, et al : Efficacy of endovascular thrombectomy in patients with M2 segment middle cerebral artery occlusions : meta-analysis of data from the HERMES Collaboration. J Neurointerv Surg 11 : 1065-1069, 2019.
 
9) Liu X, Dai Q, Ye R, et al : Endovascular treatment versus standard medical treatment for vertebrobasilar artery occlusion (BEST) : an open-label, randomised controlled trial. Lancet Neurol 19 : 115-122, 2020.
 
10) Li W, Wu C, Deng R, et al : Comparison of Perioperative Safety of Carotid Artery Stenting and Endarterectomy in the Treatment of Carotid Artery Stenosis : A Meta-Analysis of Randomized Controlled Trials. World Neurosurg 181 : e356-e375, 2024.
 
11) JET Studt Group : Japanese EC-IC Bypass Trial (JET Study) -中間解析結果 (第二報) -. 脳卒中の外科 30 : 434-437, 2002.
 
12) Powers WJ, Clarke WR, Grubb RL Jr, et al : Extracranial-intracranial bypass surgery for stroke prevention in hemodynamic cerebral ischemia : the Carotid Occlusion Surgery Study randomized trial. JAMA 306 : 1983-1992, 2011.
 
13) Ma Y, Wang T, Wang H, et al : Extracranial-Intracranial Bypass and Risk of Stroke and Death in Patients With Symptomatic Artery Occlusion : The CMOSS Randomized Clinical Trial. JAMA 330 : 704-714, 2023.
 
14) Yeo JYP, Yau CE, Ong NY, et al : Comparing the Impact of Stenting vs. Medical Therapy for Intracranial Arterial Stenosis : A Systematic Review and One-stage and Two-stage Meta-Analysis of Randomized Clinical Trials. Clin Neuroradiol 34 : 379-390, 2024.
 
P.62 掲載の参考文献
1) Special report from the National Institute of Neurological Disorders and Stroke. Classification of cerebrovascular diseases III. Stroke 21 : 637-676, 1990.
PubMed
2) Easton JD, Saver JL, Albers GW, et al : Definition and evaluation of transient ischemic attack : a scientific statement for healthcare professionals from the American Heart Association/American Stroke Association Stroke Council ; Council on Cardiovascular Surgery and Anesthesia ; Council on Cardiovascular Radiology and Intervention ; Council on Cardiovascular Nursing ; and the Interdisciplinary Council on Peripheral Vascular Disease. The American Academy of Neurology affirms the value of this statement as an educational tool for neurologists. Stroke 40 : 2276-2293, 2009.
 
3) Kiyohara T, Kamouchi M, Kumai Y, et al : ABCD3 and ABCD3-I scores are superior to ABCD2 score in the prediction of short- and long-term risks of stroke after transient ischemic attack. Stroke 45 : 418-425, 2014.
 
4) Purroy F, Montaner J, Molina CA, et al : Patterns and predictors of early risk of recurrence after transient ischemic attack with respect to etiologic subtypes. Stroke 38 : 3225-3229, 2007.
 
5) 尾原知行, 山本康正, 永金義成, ほか : 一過性脳虚血発作 (TIA) の病型分類-ラクナTIAの臨床的重要性-. 臨床神経学 51 : 406-411, 2011.
 
6) Merwick A, Albers GW, Amarenco P, et al : Addition of brain and carotid imaging to the ABCD2 score to identify patients at early risk of stroke after transient ischaemic attack : a multicentre observational study. Lancet Neurol 9 : 1060-1069, 2010.
 
7) Lavallee PC, Meseguer E, Abboud H, et al : A transient ischaemic attack clinic with round-the-clock access (SOS-TIA) : feasibility and effects. Lancet Neurol 6 : 953-960, 2007.
 
8) Giles MF, Albers GW, Amarenco P, et al : Early stroke risk and ABCD2 score performance in tissue-vs time-defined TIA : a multicenter study. Neurology 77 : 1222-1228, 2011.
 
9) Adams HP Jr, Bendixen BH, Kappelle LJ, et al : Classification of subtype of acute ischemic stroke. Definitions for use in a multicenter clinical trial. TOAST. Trial of Org 10172 in Acute Stroke Treatment. Stroke 24 : 35-41, 1993.
 
10) Feinberg WM, Albers GW, Barnett HJ, et al : Guidelines for the management of transient ischemic attacks. From the Ad Hoc Committee on Guidelines for the Management of Transient Ischemic Attacks of the Stroke Council of the American Heart Association. Circulation 89 : 2950-2965, 1994.
 
11) Uchiyama S, Hoshino T, Sissani L, et al : Japanese Versus Non-Japanese Patients with Transient Ischemic Attack or Minor Stroke : Subanalysis of TIA registry.org. J Stroke Cerebrovasc Dis 28 : 2232-2241, 2019.
 
12) Lavallee PC, Sissani L, Labreuche J, et al : Clinical Significance of Isolated Atypical Transient Symptoms in a Cohort With Transient Ischemic Attack. Stroke 48 : 1495-1500, 2017.
 
13) Giles MF, Rothwell PM : Risk of stroke early after transient ischaemic attack : a systematic review and meta-analysis. Lancet Neurol 6 : 1063-1072, 2007.
PubMed
14) Rothwell PM, Giles MF, Chandratheva A, et al : Effect of urgent treatment of transient ischaemic attack and minor stroke on early recurrent stroke (EXPRESS study) : a prospective population-based sequential comparison. Lancet 370 : 1432-1442, 2007.
 
15) Johnston SC, Rothwell PM, Nguyen-Huynh MN, et al : Validation and refinement of scores to predict very early stroke risk after transient ischaemic attack. Lancet 369 : 283-292, 2007.
 
16) Amin HP, Madsen TE, Bravata DM, et al ; American Heart Association Emergency Neurovascular Care Committee of the Stroke Council and Council on Peripheral Vascular Disease : Diagnosis, Workup, Risk Reduction of Transient Ischemic Attack in the Emergency Department Setting : A Scientific Statement From the American Heart Association. Stroke 54 : e109-e121, 2023.
 
17) Epstein KA, Viscoli CM, Spence JD, et al : Smoking cessation and outcome after ischemic stroke or TIA. Neurology 89 : 1723-1729, 2017.
 
18) Amarenco P, Bogousslavsky J, Callahan A 3rd, et al : High-dose atorvastatin after stroke or transient ischemic attack. N Engl J Med 355 : 549-559, 2006.
 
19) Wang Y, Wang Y, Zhao X, et al : Clopidogrel with aspirin in acute minor stroke or transient ischemic attack. N Engl J Med 369 : 11-19, 2013.
 
20) Johnston SC, Easton JD, Farrant M, et al : Clopidogrel and Aspirin in Acute Ischemic Stroke and High-Risk TIA. N Engl J Med 379 : 215-225, 2018.
 
21) Rahman H, Khan SU, Nasir F, et al : Optimal Duration of Aspirin Plus Clopidogrel After Ischemic Stroke or Transient Ischemic Attack. Stroke 50 : 947-953, 2019.
 
22) Steffel J, Collins R, Antz M, et al : 2021 European Heart Rhythm Association Practical Guide on the Use of Non-Vitamin K Antagonist Oral Anticoagulants in Patients with Atrial Fibrillation. Europace 23 : 1612-1676, 2021.
 
23) Kimura S, Toyoda K, Yoshimura S, et al : Practical "1-2-3-4-Day" Rule for Starting Direct Oral Anticoagulants After Ischemic Stroke With Atrial Fibrillation : Combined Hospital-Based Cohort Study. Stroke 53 : 1540-1549, 2022.
 
P.68 掲載の参考文献
1) Ariesen MJ, Claus SP, Rinkel GJ, et al : Risk factors for intracerebral hemorrhage in the general population : a systematic review. Stroke 34 : 2060-2065, 2003.
 
2) PROGRESS Collaborative Group : Randomised trial of a perindopril-based blood-pressure-lowering regimen among 6,105 individuals with previous stroke or transient ischaemic attack. Lancet 358 : 1033-1041, 2001.
PubMed
3) Bokura H, Saika R, Yamaguchi T, et al : Microbleeds are associated with subsequent hemorrhagic and ischemic stroke in healthy elderly individuals. Stroke 42 : 1867-1871, 2011.
 
4) Al-Shahi Salman R, Frantzias J, Lee RJ, et al : Absolute risk and predictors of the growth of acute spontaneous intracerebral haemorrhage : a systematic review and meta-analysis of individual patient data. Lancet Neurol 17 : 885-894, 2018.
 
5) 山口玲, 宮原牧子, 寺野成彦, ほか : くも膜下出血を伴わない脳内出血で発症した破裂脳動脈瘤の検討. 脳卒中の外科 40 : 328-331, 2012.
 
6) Gross BA, Du R : Natural history of cerebral arteriovenous malformations : a meta-analysis. J Neurosurg 118 : 437-443, 2013.
PubMed
7) Mohr JP, Parides MK, Stapf C, et al : Medical management with or without interventional therapy for unruptured brain arteriovenous malformations (ARUBA) : a multicentre, non-blinded, randomised trial. Lancet 383 : 614-621, 2014.
 
8) Miyamoto S ; The Japan Adult Moyamoya Trial Group : Study design for a prospective randomized trial of extracranial-intracranial bypass surgery for adults with moyamoya disease and hemorrhagic onset-The Japan Adult Moyamoya Trial Group. Neurol Med Chir (Tokyo) 44 : 218-219, 2004.
 
9) Takahashi JC, Funaki T, Houkin K, et al : Significance of the Hemorrhagic Site for Recurrent Bleeding : Prespecified Analysis in the Japan Adult Moyamoya Trial. Stroke 47 : 37-43, 2016.
 
10) Funaki T, Takahashi JC, Houkin K, et al : Angiographic features of hemorrhagic moyamoya disease with high recurrence risk : a supplementary analysis of the Japan Adult Moyamoya Trial. J Neurosurg 128 : 777-784, 2018.
 
11) Singh V, Smith WS, Lawton MT, et al : Risk factors for hemorrhagic presentation in patients with dural arteriovenous fistulae. Neurosurgery 62 : 628-635, 2008.
 
12) Ferro JM, Canhao P, Stam J, et al : Prognosis of cerebral vein and dural sinus thrombosis : results of the International Study on Cerebral Vein and Dural Sinus Thrombosis (ISCVT). Stroke 35 : 664-670, 2004.
 
13) Duman T, Uluduz D, Midi I, et al : A Multicenter Study of 1144 Patients with Cerebral Venous Thrombosis : The VENOST Study. J Stroke Cerebrovasc Dis 26 : 1848-1857, 2017.
 
14) Jakel L, De Kort AM, Klijn CJM, et al : Prevalence of cerebral amyloid angiopathy : A systematic review and meta-analysis. Alzheimers Dement 18 : 10-28, 2022.
 
15) Greenberg SM, Charidimou A : Diagnosis of Cerebral Amyloid Angiopathy : Evolution of the Boston Criteria. Stroke 49 : 491-497, 2018.
 
P.74 掲載の参考文献
1) 飯原弘二 : 脳神経外科学 [改訂11版] (太田富雄総編集), 金芳堂, 2012.
 
2) 脳卒中治療ガイドライン 2021 [改訂2023] (日本脳卒中学会脳卒中ガイドライン委員会編), 協和企画, 2023.
 
3) 中川原譲二 : 病型別, 年代別, 性別にみた脳卒中の地域間 (札幌と全国) 比較. 脳卒中データバンク 2005 (小林祥泰編), p34-35, 中山書店, 2005.
 
4) 荒木信夫, 高木誠, 厚東篤生 : 脳卒中ビジュアルテキスト [第4版], 医学書院, 2015.
 
5) 脳出血・くも膜下出血診療読本 (豊田一則, 高橋淳編著), 中外医学社, 2016.
 
6) 決定版 頭部画像診断パーフェクト (土屋一洋, 前田正幸, 藤川章編), 羊土社, 2011.
 
P.81 掲載の参考文献
1) 高木康志, ほか : 脳出血. 脳卒中治療ガイドライン 2021 改訂 2023 (日本脳卒中学会脳卒中ガイドライン委員会編), p126, 協和企画, 2023.
 
2) 高木康志, ほか : 脳出血. 脳卒中治療ガイドライン 2021 改訂 2023 (日本脳卒中学会脳卒中ガイドライン委員会編), p127-129, 協和企画, 2023.
 
3) 高木康志, ほか : 脳出血. 脳卒中治療ガイドライン 2021 改訂 2023 (日本脳卒中学会脳卒中ガイドライン委員会編), p130, 協和企画, 2023.
 
4) 高木康志, ほか : 脳出血. 脳卒中治療ガイドライン 2021 改訂 2023 (日本脳卒中学会脳卒中ガイドライン委員会編), p124-125, 協和企画, 2023.
 
5) 高木康志, ほか : 脳出血. 脳卒中治療ガイドライン 2021 改訂 2023 (日本脳卒中学会脳卒中ガイドライン委員会編), p131-132, 協和企画, 2023.
 
6) Doria JW, Forgacs PB : Incidence, Implications, and Management of Seizures Following Ischemic and Hemorrhagic Stroke. Curr Neurol Neurosci Rep 19 : 37, 2019.
 
7) 高木康志, ほか : 脳出血. 脳卒中治療ガイドライン 2021 改訂 2023 (日本脳卒中学会脳卒中ガイドライン委員会編), p135-139, 協和企画, 2023.
 
8) Kashiwazaki D, Tomita T, Shibata T, et al : Impact of perihematomal edema on infectious complications after spontaneous intracerebral hemorrhage. J Stroke Cerebrovasc Dis 30 : 105827, 2021.
 
9) 高木康志, ほか : 脳出血. 脳卒中治療ガイドライン 2021 改訂 2023 (日本脳卒中学会脳卒中ガイドライン委員会編), p133-134, 協和企画, 2023.
 
10) 岡田靖, ほか : その他の脳血管障害. 脳卒中治療ガイドライン 2021 改訂 2023 (日本脳卒中学会脳卒中ガイドライン委員会編), p238-240, 協和企画, 2023.
 
11) 角田亘, ほか : 亜急性期以後のリハビリテーション診療. 脳卒中治療ガイドライン 2021 改訂 2023 (日本脳卒中学会脳卒中ガイドライン委員会編), p299, 協和企画, 2023.
 
12) Haapaniemi E, Strbian D, Rossi C, et al : The CAVE score for predicting late seizures after intracerebral hemorrhage. Stroke 45 : 1971-1976, 2014.
PubMed
13) 高木康志, ほか : 脳出血. 脳卒中治療ガイドライン 2021 改訂 2023 (日本脳卒中学会脳卒中ガイドライン委員会編), p140-142, 協和企画, 2023.
 
14) 高木康志, ほか : 脳出血. 脳卒中治療ガイドライン 2021 改訂 2023 (日本脳卒中学会脳卒中ガイドライン委員会編), p143-146, 協和企画, 2023.
 
15) 高木康志, ほか : 脳出血. 脳卒中治療ガイドライン 2021 改訂 2023 (日本脳卒中学会脳卒中ガイドライン委員会編), p147-148, 協和企画, 2023.
 
P.87 掲載の参考文献
1) de Rooij NK, Linn FH, van der Plas JA, et al : Incidence of subarachnoid haemorrhage : a systematic review with emphasis on region, age, gender and time trends. J Neurol Neurosurg Psychiatry 78 : 1365-1372, 2007.
 
2) UCAS Japan Investigators ; Morita A, Kirino T, Hashi K, et al : The natural course of unruptured cerebral aneurysms in a Japanese cohort. N Engl J Med 366 : 2474-2482, 2012.
 
3) Chalard K, Szabo V, Pavillard F, et al : Long-term outcome in patients with aneurysmal subarachnoid hemorrhage requiring mechanical ventilation. PLoS One 16 : e0247942, 2021.
 
4) Huang J, van Gelder JM : The probability of sudden death from rupture of intracranial aneurysms : a meta-analysis. Neurosurgery 51 : 1101-1107, 2002.
 
5) Hasegawa Y, Uchikawa H, Kajiwara S, et al : Central sympathetic nerve activation in subarachnoid hemorrhage. J Neurochem 160 : 34-50, 2022.
 
6) 安井敏裕, 岸廣成, 小宮山雅樹, ほか : 来院後早期に再破裂を来たした破裂脳動脈瘤症例の検討. 脳神経外科 22 : 1119-1122, 1994.
 
7) Foreman PM, Starke RM, Hendrix P, et al : Endothelin polymorphisms as a risk factor for cerebral aneurysm rebleeding following aneurysmal subarachnoid hemorrhage. Clin Neurol Neurosurg 157 : 65-69, 2017.
 
8) Fang Y, Huang L, Wang X, et al : A new perspective on cerebrospinal fluid dynamics after subarachnoid hemorrhage : From normal physiology to pathophysiological changes. J Cereb Blood Flow Metab 42 : 543-558, 2022.
 
9) Kirkpatrick PJ, Turner CL, Smith C, et al : Simvastatin in aneurysmal subarachnoid haemorrhage (STASH) : a multicentre randomised phase 3 trial. Lancet Neurol 13 : 666-675, 2014.
 
10) Macdonald RL, Higashida RT, Keller E, et al : Clazosentan, an endothelin receptor antagonist, in patients with aneurysmal subarachnoid haemorrhage undergoing surgical clipping : a randomised, double-blind, placebo-controlled phase 3 trial (CONSCIOUS-2). Lancet Neurol 10 : 618-625, 2011.
 
11) Cahill J, Zhang JH : Subarachnoid hemorrhage : is it time for a new direction? Stroke 40 : S86-S87, 2009.
 
12) Hasegawa S, Hasegawa Y, Miura M : Current Therapeutic Drugs Against Cerebral Vasospasm after Subarachnoid Hemorrhage : A Comprehensive Review of Basic and Clinical Studies. Curr Drug Deliv 14 : 843-852, 2017.
 
13) Vergouwen MD, Vermeulen M, van Gijn J, et al : Definition of delayed cerebral ischemia after aneurysmal subarachnoid hemorrhage as an outcome event in clinical trials and observational studies : proposal of a multidisciplinary research group. Stroke 41 : 2391-2395, 2010.
 
14) Rass V, Gaasch M, Kofler M, et al : Systemic Inflammatory Response Syndrome as Predictor of Poor Outcome in Nontraumatic Subarachnoid Hemorrhage Patients. Crit Care Med 46 : e1152-e1159, 2018.
 
P.94 掲載の参考文献
1) Macdonald RL, Schweizer TA : Spontaneous subarachnoid haemorrhage. Lancet 389 : 655-666, 2017.
 
2) Harada K, Fukuyama K, Shirouzu T, et al : Prevalence of unruptured intracranial aneurysms in healthy asymptomatic Japanese adults : differences in gender and age. Acta Neurochir (Wien) 155 : 2037-2043, 2013.
 
3) Greving JP, Wermer MJ, Brown RD Jr, et al : Development of the PHASES score for prediction of risk of rupture of intracranial aneurysms : a pooled analysis of six prospective cohort studies. Lancet Neurol 13 : 59-66, 2014.
PubMed
4) Tominari S, Morita A, Ishibashi T, et al : Prediction model for 3-year rupture risk of unruptured cerebral aneurysms in Japanese patients. Ann Neurol 77 : 1050-1059, 2015.
 
5) Perry JJ, Stiell IG, Sivilotti ML, et al : Clinical decision rules to rule out subarachnoid hemorrhage for acute headache. JAMA 310 : 1248-1255, 2013.
 
6) Perry JJ, Stiell IG, Sivilotti ML, et al : Sensitivity of computed tomography performed within six hours of onset of headache for diagnosis of subarachnoid haemorrhage : prospective cohort study. BMJ 343 : d4277, 2011.
PubMed
7) Dubosh NM, Bellolio MF, Rabinstein AA, et al : Sensitivity of Early Brain Computed Tomography to Exclude Aneurysmal Subarachnoid Hemorrhage : A Systematic Review and Meta-Analysis. Stroke 47 : 750-755, 2016.
 
8) Mitchell P, Wilkinson ID, Hoggard N, et al : Detection of subarachnoid haemorrhage with magnetic resonance imaging. J Neurol Neurosurg Psychiatry 70 : 205-211, 2001.
 
9) Westerlaan HE, van Dijk JM, Jansen-van der Weide MC, et al : Intracranial aneurysms in patients with subarachnoid hemorrhage : CT angiography as a primary examination tool for diagnosis-systematic review and meta-analysis. Radiology 258 : 134-145, 2011.
 
10) Mohan M, Islim AI, Rasul FT, et al : Subarachnoid haemorrhage with negative initial neurovascular imaging : a systematic review and meta-analysis. Acta Neurochir (Wien) 161 : 2013-2026, 2019.
 
11) Lai PMR, Ng I, Gormley WB, et al : Familial Predisposition and Differences in Radiographic Patterns in Spontaneous Nonaneurysmal Subarachnoid Hemorrhage. Neurosurgery 88 : 413-419, 2021.
 
12) UCAS Japan Investigators, Morita A, Kirino T, et al : The natural course of unruptured cerebral aneurysms in a Japanese cohort. N Engl J Med 366 : 2474-2482, 2012.
 
13) Dinia L, Vert C, Gramegna LL, et al : Wall enhancement as a biomarker of intracranial aneurysm instability : a histo-radiological study. Acta Neurochir (Wien) 165 : 2783-2791, 2023.
 
14) Erhart DK, Ludolph AC, Althaus K : RCVS : by clinicians for clinicians-a narrative review. J Neurol 270 : 673-688, 2023.
 
P.100 掲載の参考文献
1) 日本脳卒中データバンク事務局 : 脳卒中レジストリを用いた我が国の脳卒中診療実態の把握 (日本脳卒中データバンク) 」報告書, 2023. [https://strokedatabank.ncvc.go.jp/f12kQnRl/wp-content/uploads/%E6%97%A5%E6%9C%AC%E8%84%B3%E5%8D%92%E4%B8%AD%E3%83%87%E3%83%BC%E3%82%BF%E3%83%90%E3%83%B3%E3%82%AF%E5%A0%B1%E5%91%8A%E6%9B%B82023%E5%B9%B4_20240129.pdf] (2024年5月閲覧)
 
2) Molyneux AJ, Birks J, Clarke A, et al : The durability of endovascular coiling versus neurosurgical clipping of ruptured cerebral aneurysms : 18 year follow-up of the UK cohort of the International Subarachnoid Aneurysm Trial (ISAT). Lancet 385 : 691-697, 2015.
 
3) Spetzler RF, McDougall CG, Zabramski JM, et al : The Barrow Ruptured Aneurysm Trial : 6-year results. J Neurosurg 123 : 609-617, 2015.
 
4) 井川房夫, 日高敏和, 黒川泰玄, ほか : 本邦の脳動脈瘤治療の現状-当院, 脳卒中データバンク, (社) 日本脳神経外科学会調査より-. 脳卒中の外科 43 : 262-266, 2015.
 
5) Kurogi R, Kada A, Ogasawara K, et al : Effects of case volume and comprehensive stroke center capabilities on patient outcomes of clipping and coiling for subarachnoid hemorrhage. J Neurosurg 134 : 929-939, 2020.
 
6) Hanel RA, Cortez GM, Lopes DK, et al : Prospective study on embolization of intracranial aneurysms with the pipeline device (PREMIER study) : 3-year results with the application of a flow diverter specific occlusion classification. J Neurointerv Surg 15 : 248-254, 2023.
 
7) 日本脳神経外科学会, 日本脳卒中学会, 日本脳神経血管内治療学会 : 頭蓋内動脈ステント (脳動脈瘤治療用Flow Diverter) 適正使用指針 第3版, 2020. [http://www.jsnet.website/contents/%93K%90%B3%8Eg%97p%8Ew%90j/FD%93K%90%B3%8Eg%97p%8Ew%90j%20FIN3.pdf] (2024年5月閲覧)
 
8) Becske T, Brinjikji W, Potts MB, et al : Long-Term Clinical and Angiographic Outcomes Following Pipeline Embolization Device Treatment of Complex Internal Carotid Artery Aneurysms : Five-Year Results of the Pipeline for Uncoilable or Failed Aneurysms Trial. Neurosurgery 80 : 40-48, 2017.
 
9) Arthur AS, Molyneux A, Coon AL, et al : The safety and effectiveness of the Woven EndoBridge (WEB) system for the treatment of wide-necked bifurcation aneurysms : final 12-month results of the pivotal WEB Intrasaccular Therapy (WEB-IT) Study. J Neurointerv Surg 11 : 924-930, 2019.
 
10) Fiorella D, Molyneux A, Coon A, et al : Safety and effectiveness of the Woven EndoBridge (WEB) system for the treatment of wide necked bifurcation aneurysms : final 5 year results of the pivotal WEB Intra-saccular Therapy study (WEB-IT). J Neurointerv Surg 15 : 1175-1180, 2023.
 
11) Endo H, Hagihara Y, Kimura N, et al : Effects of clazosentan on cerebral vasospasm-related morbidity and all-cause mortality after aneurysmal subarachnoid hemorrhage : two randomized phase 3 trials in Japanese patients. J Neurosurg 137 : 1707-1717, 2022.
 
P.104 掲載の参考文献
1) Ferro JM, Canhao P, Stam J, et al : Prognosis of cerebral vein and dural sinus thrombosis : results of the International Study on Cerebral Vein and Dural Sinus Thrombosis (ISCVT). Stroke 35 : 664-670, 2004.
 
2) Coutinho JM, Zuurbier SM, Aramideh M, et al : The incidence of cerebral venous thrombosis : a cross-sectional study. Stroke 43 : 3375-3377, 2012.
 
3) Devasagayam S, Wyatt B, Leyden J, et al : Cerebral Venous Sinus Thrombosis Incidence Is Higher Than Previously Thought : A Retrospective Population-Based Study. Stroke 47 : 2180-2182, 2016.
 
4) Takemaru M, Kuriyama M, Himeno T, et al : Cerebral Venous Sinus Thrombosis : Incidence and Hyperhomocysteinemia as a Risk Factor in Japanese Patients. J Neuro Neurosci 8 : 219, 2017.
 
5) Ulivi L, Squitieri M, Cohen H, et al : Cerebral venous thrombosis : a practical guide. Pract Neurol 20 : 356-367, 2020.
 
6) Masuhr F, Mehraein S, Einhaupl K : Cerebral venous and sinus thrombosis. J Neurol 251 : 11-23, 2004.
 
7) Einhaupl KM, Villringer A, Meister W, et al : Heparin treatment in sinus venous thrombosis. Lancet 338 : 597-600, 1991.
PubMed
8) 脳卒中治療ガイドライン 2021 [改訂2023] (日本脳卒中学会脳卒中ガイドライン委員会編), p225-227, 協和企画, 2023.
 
P.110 掲載の参考文献
1) Suzuki J, Takaku A : Cerebrovascular "moyamoya" disease. Disease showing abnormal net-like vessels in base of brain. Arch Neurol 20 : 288-299, 1969.
PubMed
2) Ahn HS, Kazmi SZ, Kang T, et al : Familial Risk for Moyamoya Disease Among First-Degree Relatives, Based on a Population-Based Aggregation Study in Korea. Stroke 51 : 2752-2760, 2020.
 
3) Liu W, Morito D, Takashima S, et al : Identification of RNF213 as a susceptibility gene for moyamoya disease and its possible role in vascular development. PLoS One 6 : e22542, 2011.
 
4) Kamada F, Aoki Y, Narisawa A, et al : A genome-wide association study identifies RNF213 as the first Moyamoya disease gene. J Hum Genet 56 : 34-40, 2011.
 
5) Tashiro R, Fujimura M, Katsuki M, et al : Prolonged/delayed cerebral hyperperfusion in adult patients with moyamoya disease with RNF213 gene polymorphism c.14576G>A (rs112735431) after superficial temporal artery-middle cerebral artery anastomosis. J Neurosurg 135 : 417-424, 2020.
 
6) Miyatake S, Miyake N, Touho H, et al : Homozygous c.14576G>A variant of RNF213 predicts early-onset and severe form of moyamoya disease. Neurology 78 : 803-810, 2012.
 
7) Miyawaki S, Imai H, Shimizu M, et al : Genetic variant RNF213 c.14576G > A in various phenotypes of intracranial major artery stenosis/occlusion. Stroke 44 : 2894-2897, 2013.
 
8) Ozaki D, Endo H, Tashiro R, et al : Association between RNF213 c.14576G > A Variant (rs112735431) and Peripheral Pulmonary Artery Stenosis in Moyamoya Disease. Cerebrovasc Dis 51 : 282-287, 2022.
 
9) Yamada I, Murata Y, Umehara I, et al : SPECT and MRI evaluations of the posterior circulation in moyamoya disease. J Nucl Med 37 : 1613-1617, 1996.
 
10) Miyamoto S, Yoshimoto T, Hashimoto N, et al : Effects of extracranial-intracranial bypass for patients with hemorrhagic moyamoya disease : results of the Japan Adult Moyamoya Trial. Stroke 45 : 1415-1421, 2014.
 
11) Fujimura M, Tominaga T : Lessons learned from moyamoya disease : outcome of direct/indirect revascularization surgery for 150 affected hemispheres. Neurol Med Chir (Tokyo) 52 : 327-332, 2012.
PubMed
12) Kanoke A, Fujimura M, Tashiro R, et al : Transient Global Cerebral Hypoperfusion as a Characteristic Cerebral Hemodynamic Pattern in the Acute Stage after Combined Revascularization Surgery for Pediatric Moyamoya Disease : N-Isopropyl-P- [123I] Iodoamphetamine Single-Photon Emission Computed Tomography Study. Cerebrovasc Dis 51 : 453-460, 2022.
 
13) Hayashi T, Kimiwada T, Karibe H, et al : Preoperative Risks of Cerebral Infarction in Pediatric Moyamoya Disease. Stroke 52 : 2302-2310, 2021.
 
14) Kuroda S, Yamamoto S, Funaki T, et al : Five-Year Stroke Risk and Its Predictors in Asymptomatic Moyamoya Disease : Asymptomatic Moyamoya Registry (AMORE). Stroke 54 : 1494-1504, 2023.
 
15) 舟木健史, 高橋淳, 宮本享 ; JAM Trial Group : 出血型もやもや病治療の新たな展開. 脳神経外科ジャーナル 28 : 149-155, 2019.
 
P.116 掲載の参考文献
1) 日本循環器学会 : 肺血栓塞栓症および深部静脈血栓症の診断, 治療, 予防に関するガイドライン (2017年改訂版), 2020. [https://www.j-circ.or.jp/cms/wp-content/uploads/2017/09/JCS2017_ito_h.pdf]
 
2) 門平靖子, 森下英理子 : 先天性血栓性素因の診断と治療 (1) : AT, PC, PS欠乏症. 日本血栓止血学会誌 30 : 14-18, 2019.
 
3) 鈴木伸明, 小嶋哲人 : 先天性血栓性素因の診断と治療 (2) : APCレジスタンス/ライデン異常, アンチトロンビン抵抗性, 他. 日本血栓止血学会誌 30 : 19-22, 2019.
 
4) Elliott CG : Pulmonary physiology during pulmonary embolism. Chest 101 (4 Suppl) : 163S-171S, 1992.
 
5) Ansari A : Acute and chronic pulmonary thromboembolism : current perspectives. Part II : Etiology, pathology, pathogenesis, and pathophysiology. Clin Cardiol 9 : 449-456, 1986.
 
6) Goldhaber SZ, Elliott CG : Acute pulmonary embolism : part I : epidemiology, pathophysiology, and diagnosis. Circulation 108 : 2726-2729, 2003.
 
7) Moser KM : Pulmonary embolism. Am Rev Respir Dis 115 : 829-852, 1977.
 
8) Sharma GV, McIntyre KM, Sharma S, et al : Clinical and hemodynamic correlates in pulmonary embolism. Clin Chest Med 5 : 421-437, 1984.
 
9) Sekioka K, Tanaka T, Hayashi T, et al : Right ventricular function under acute cor pulmonale. Jpn Circ J 53 : 1269-1277, 1989.
 
10) Visner MC, Arentzen CE, O'Connor MJ, et al : Alterations in left ventricular three-dimensional dynamic geometry and systolic function during acute right ventricular hypertension in the conscious dog. Circulation 67 : 353-365, 1983.
 
11) Morgan TE, Edmunds LH Jr : Pulmonary artery occlusion. 3. Biochemical alterations. J Appl Physiol 22 : 1012-1016, 1967.
 
12) Konstantinides S, Geibel A, Kasper W, et al : Patent foramen ovale is an important predictor of adverse outcome in patients with major pulmonary embolism. Circulation 97 : 1946-1951, 1998.
 
13) Tsao MS, Schraufnagel D, Wang NS : Pathogenesis of pulmonary infarction. Am J Med 72 : 599-606, 1982.
 
14) Dalen JE, Haffajee CI, Alpert JS 3rd, et al : Pulmonary embolism, pulmonary hemorrhage and pulmonary infarction. N Engl J Med 296 : 1431-1435, 1977.
 
15) Schraufnagel DE, Tsao MS, Yao YT, et al : Factors associated with pulmonary infarction. A discriminant analysis study. Am J Clin Pathol 84 : 15-18, 1985.
 
P.119 掲載の参考文献
1) Goldhaber SZ, Elliott CG : Acute pulmonary embolism : part I : epidemiology, pathophysiology, and diagnosis. Circulation 108 : 2726-2729, 2003.
 
2) Sekioka K, Tanaka T, Hayashi T, et al : Right ventricular function under acute cor pulmonale. Jpn Circ J 53 : 1269-1277, 1989.
 
3) Sharma GV, Sasahara AA : Regional and transmural myocardial blood flow studies in experimental pulmonary embolism. Prog Cardiovasc Dis 17 : 191-198, 1974.
 
4) Tsao MS, Schraufnagel D, Wang NS : Pathogenesis of pulmonary infarction. Am J Med 72 : 599-606, 1982.
 
5) Nakamura M, Yamada N, Ito M : Current management of venous thromboembolism in Japan : Current epidemiology and advances in anticoagulant therapy. J Cardiol 66 : 451-459, 2015.
 
6) Sakuma M, Nakamura M, Yamada N, et al : Venous thromboembolism : deep vein thrombosis with pulmonary embolism, deep vein thrombosis alone, and pulmonary embolism alone. Circ J 73 : 305-309, 2009.
 
7) Poe ND, Dore EK, Swanson LA, et al : Fatal pulmonary embolism. J Nucl Med 10 : 28-33, 1969.
 
8) Goldhaber SZ, Morpurgo M : Diagnosis, treatment, and prevention of pulmonary embolism. Report of the WHO/International Society and Federation of Cardiology Task Force. JAMA 268 : 1727-1733, 1992.
 
9) Yamashita Y, Morimoto T, Kadota K, et al : Severity of pulmonary embolism at initial diagnosis and long-term clinical outcomes : From the COMMAND VTE Registry. Int J Cardiol 343 : 107-113, 2021.
 
10) Wells PS, Anderson DR, Rodger M, et al : Derivation of a simple clinical model to categorize patients probability of pulmonary embolism : increasing the models utility with the SimpliRED D-dimer. Thromb Haemost 83 : 416-420, 2000.
 
11) Le Gal G, Righini M, Roy PM, et al : Prediction of pulmonary embolism in the emergency department : the revised Geneva score. Ann Intern Med 144 : 165-171, 2006.
 
12) Gibson NS, Sohne M, Kruip MJ, et al : Further validation and simplification of the Wells clinical decision rule in pulmonary embolism. Thromb Haemost 99 : 229-234, 2008.
 
13) Klok FA, Mos IC, Nijkeuter M, et al : Simplification of the revised Geneva score for assessing clinical probability of pulmonary embolism. Arch Intern Med 168 : 2131-2136, 2008.
 
14) Ceriani E, Combescure C, Le Gal G, et al : Clinical prediction rules for pulmonary embolism : a systematic review and meta-analysis. J Thromb Haemost 8 : 957-970, 2010.
 
15) Stein PD, Hull RD, Patel KC, et al : D-dimer for the exclusion of acute venous thrombosis and pulmonary embolism : a systematic review. Ann Intern Med 140 : 589-602, 2004.
 
16) Konstantinides SV, Meyer G, Becattini C, et al : 2019 ESC Guidelines for the diagnosis and management of acute pulmonary embolism developed in collaboration with the European Respiratory Society (ERS). Eur Heart J 41 : 543-603, 2020.
 
P.127 掲載の参考文献
1) 肺血栓塞栓症および深部静脈血栓症の診断, 治療, 予防に関するガイドライン (2017年改訂版), 2020. [https://www.j-circ.or.jp/cms/wp-content/uploads/2017/09/JCS2017_ito_h.pdf]
 
2) Jaff MR, McMurtry MS, Archer SL, et al : Management of massive and submassive pulmonary embolism, iliofemoral deep vein thrombosis, and chronic thromboembolic pulmonary hypertension : a scientific statement from the American Heart Association. Circulation 123 : 1788-1830, 2011.
 
3) Konstantinides SV, Meyer G, Becattini C, et al : 2019 ESC Guidelines for the diagnosis and management of acute pulmonary embolism developed in collaboration with the European Respiratory Society (ERS). Eur Heart J 41 : 543-603, 2020.
 
4) Fukuda I, Daitoku K : Surgical Embolectomy for Acute Pulmonary Thromboembolism. Ann Vasc Dis 10 : 107-114, 2017.
 
5) Hussain ST, Bartholomew JR, Leacche M, et al : Retrograde Pulmonary Embolectomy for Acute Pulmonary Embolism : A Simplified Technique. Ann Thorac Surg 103 : e473-e474, 2017.
 
6) Zarrabi K, Zolghadrasli A, Ostovan MA, et al : Short-term results of retrograde pulmonary embolectomy in massive and submassive pulmonary embolism : a single-center study of 30 patients. Eur J Cardiothorac Surg 40 : 890-893, 2011.
 
7) Spagnolo S, Barbato L, Grasso MA, et al : Retrograde pulmonary perfusion as an adjunct to standard pulmonary embolectomy for acute pulmonary embolism. Multimed Man Cardiothorac Surg 2014 : mmu019, 2014.
 
8) Kawahito K, Adachi H : Balloon catheter pulmonary embolectomy under direct visual control using a choledochoscope. Ann Thorac Surg 91 : 621-623, 2011.
 
9) Raman K, Ramanathan S, Sankar J, et al : Flexible fibre optic bronchoscopy as angioscope to ascertain completeness of pulmonary embolectomy : surgery for pulmonary embolism-how I do it. Indian J Thorac Cardiovasc Surg 38 : 118-121, 2022.
 
10) Ito R, Yamashita J, Sasaki Y, et al : Efficacy and safety of balloon pulmonary angioplasty for residual pulmonary hypertension after pulmonary endarterectomy. Int J Cardiol 334 : 105-109, 2021.
 
11) Minakawa M, Fukuda I, Miyata H, et al : Outcomes of Pulmonary Embolectomy for Acute Pulmonary Embolism. Circ J 82 : 2184-2190, 2018.
 
12) Percy ED, Shah R, Hirji S, et al : National Outcomes of Surgical Embolectomy for Acute Pulmonary Embolism. Ann Thorac Surg 110 : 441-447, 2020.
 
13) Choi JH, O'Malley TJ, Maynes EJ, et al : Surgical Pulmonary Embolectomy Outcomes for Acute Pulmonary Embolism. Ann Thorac Surg 110 : 1072-1080, 2020.
 
14) Fukuda I, Taniguchi S, Fukui K, et al : Improved outcome of surgical pulmonary embolectomy by aggressive intervention for critically ill patients. Ann Thorac Surg 91 : 728-732, 2011.
 
15) Thangudu P : From Trendelenburg to PERTs : Evolution in the Management of Massive Pulmonary Embolism. Methodist Debakey Cardiovasc J 20 : 19-26, 2024.
 
P.132 掲載の参考文献
1) Klok FA, van der Hulle T, den Exter PL, et al : The post-PE syndrome : a new concept for chronic complications of pulmonary embolism. Blood Rev 28 : 221-226, 2014.
 
2) Stevinson BG, Hernandez-Nino J, Rose G, et al : Echocardiographic and functional cardiopulmonary problems 6 months after first-time pulmonary embolism in previously healthy patients. Eur Heart J 28 : 2517-2524, 2007.
 
3) Nakano Y, Adachi S, Nishiyama I, et al : Usefulness of a refined computed tomography imaging method to assess the prevalence of residual pulmonary thrombi in patients 1 year after acute pulmonary embolism : The Nagoya PE study. J Thromb Haemost 20 : 888-898, 2022.
 
4) Smith RA, Mosesson MW, Rooney MM, et al : The role of putative fibrinogen Aalpha-, Bbeta-, and GammaA-chain integrin binding sites in endothelial cell-mediated clot retraction. J Biol Chem 272 : 22080-22085, 1997.
 
5) Bunce LA, Sporn LA, Francis CW : Endothelial cell spreading on fibrin requires fibrinopeptide B cleavage and amino acid residues 15-42 of the beta chain. J Clin Invest 89 : 842-850, 1992.
 
6) Morris TA, Marsh JJ, Chiles PG, et al : Fibrin derived from patients with chronic thromboembolic pulmonary hypertension is resistant to lysis. Am J Respir Crit Care Med 173 : 1270-1275, 2006.
 
7) Moser KM, Cantor JP, Olman M, et al : Chronic pulmonary thromboembolism in dogs treated with tranexamic acid. Circulation 83 : 1371-1379, 1991.
 
8) Sanchez O, Helley D, Couchon S, et al : Perfusion defects after pulmonary embolism : risk factors and clinical significance. J Thromb Haemost 8 : 1248-1255, 2010.
 
9) Bernard J, Yi ES : Pulmonary thromboendarterectomy : a clinicopathologic study of 200 consecutive pulmonary thromboendarterectomy cases in one institution. Hum Pathol 38 : 871-877, 2007.
 
10) Blauwet LA, Edwards WD, Tazelaar HD, et al : Surgical pathology of pulmonary thromboendarterectomy : a study of 54 cases from 1990 to 2001. Hum Pathol 34 : 1290-1298, 2003.
 
11) Zabini D, Heinemann A, Foris V, et al : Comprehensive analysis of inflammatory markers in chronic thromboembolic pulmonary hypertension patients. Eur Respir J 44 : 951-962, 2014.
 
12) Varma MR, Varga AJ, Knipp BS, et al : Neutropenia impairs venous thrombosis resolution in the rat. J Vasc Surg 38 : 1090-1098, 2003.
 
13) Zabini D, Nagaraj C, Stacher E, et al : Angiostatic Factors in The Pulmonary Endarterectomy Material from Chronic Thromboembolic Pulmonary Hypertension Patients Cause Endothelial Dysfunction. PLoS One 7 : e43793, 2012.
 
14) Varma MR, Moaveni DM, Dewyer NA, et al : Deep Vein Thrombosis Resolution is not Accelerated with Increased Neovascularization. J Vasc Surg 40 : 536-542, 2004.
 
15) Suntharalingam J, Goldsmith K, van Marion V, et al : Fibrinogen Aalpha Thr312Ala polymorphism is associated with chronic thromboembolic pulmonary hypertension. Eur Respir J 31 : 736-741, 2008.
 
16) Standeven KF, Grant PJ, Carter AM, et al : Functional analysis of the fibrinogen Aalpha Thr312Ala polymorphism : effects on fibrin structure and function. Circulation 107 : 2326-2330, 2003.
 
17) Bochenek ML, Leidinger C, Rosinus NS, et al : Activated Endothelial TGFβ1 Signaling Promotes Venous Thrombus Nonresolution in Mice Via Endothelin-1 : Potential Role for Chronic Thromboembolic Pulmonary Hypertension. Circ Res 126 : 162-181, 2020.
 
P.138 掲載の参考文献
1) Humbert M, Kovacs G, Hoeper MM, et al : 2022 ESC/ERS Guidelines for the diagnosis and treatment of pulmonary hypertension. Eur Respir J 61 : 2200879, 2023.
 
2) Fukuda K, Date H, Doi S, et al : Guidelines for the Treatment of Pulmonary Hypertension (JCS 2017/JPCPHS 2017). Circ J 83 : 842-945, 2019.
 
3) Frost A, Badesch D, Gibbs JSR, et al : Diagnosis of pulmonary hypertension. Eur Respir J 53 : 1801904, 2019.
 
4) Piazza G, Goldhaber SZ : Chronic thromboembolic pulmonary hypertension. N Engl J Med 364 : 351-360, 2011.
 
5) Riedel M, Stanek V, Widimsky J, et al : Longterm follow-up of patients with pulmonary thromboembolism. Late prognosis and evolution of hemodynamic and respiratory data. Chest 81 : 151-158, 1982.
 
6) Kinoshita H, Aoki T, Motoki H, et al : Patient Journey and Disease-Related Burden in Japanese Patients With Chronic Thromboembolic Pulmonary Hypertension : A Mixed Methods Study. Value Health Reg Issues 24 : 17-23, 2021.
 
7) 肺高血圧症治療ガイドライン [2017年改訂版] (日本循環器学会/日本肺高血圧・肺循環学会/日本呼吸器学会, ほか編), 2018.
 
8) 慢性血栓塞栓性肺高血圧症 (CTEPH) 診療ガイドライン 2022 (日本肺高血圧・肺循環学会編), 2022.
 
9) Tunariu N, Gibbs SJ, Win Z, et al : Ventilation-perfusion scintigraphy is more sensitive than multidetector CTPA in detecting chronic thromboembolic pulmonary disease as a treatable cause of pulmonary hypertension. J Nucl Med 48 : 680-684, 2007.
 
10) Bajc M, Schumichen C, Gruning T, et al : EANM guideline for ventilation/perfusion single-photon emission computed tomography (SPECT) for diagnosis of pulmonary embolism and beyond. Eur J Nucl Med Mol Imaging 46 : 2429-2451, 2019.
 
11) Dong C, Zhou M, Liu D, et al : Diagnostic accuracy of computed tomography for chronic thromboembolic pulmonary hypertension : a systematic review and meta-analysis. PLoS One 10 : e0126985, 2015.
 
12) Rajaram S, Swift AJ, Telfer A, et al : 3D contrast-enhanced lung perfusion MRI is an effective screening tool for chronic thromboembolic pulmonary hypertension : results from the ASPIRE Registry. Thorax 68 : 677-678, 2013.
 
13) Ota H, Sugimura K, Miura M, et al : Four-dimensional flow magnetic resonance imaging visualizes drastic change in vortex flow in the main pulmonary artery after percutaneous transluminal pulmonary angioplasty in a patient with chronic thromboembolic pulmonary hypertension. Eur Heart J 36 : 1630, 2015.
 
P.143 掲載の参考文献
1) Delcroix M, Torbicki A, Gopalan D, et al : ERS statement on chronic thromboembolic pulmonary hypertension. Eur Respir J 57 : 2002828, 2021.
 
2) Ogo T, Shimokawahara H, Kinoshita H, et al : Selexipag for the treatment of chronic thromboembolic pulmonary hypertension. Eur Respir J 60 : 2101694, 2022.
 
3) Nakano Y, Adachi S, Nishiyama I, et al : Usefulness of a refined computed tomography imaging method to assess the prevalence of residual pulmonary thrombi in patients 1 year after acute pulmonary embolism : The Nagoya PE study. J Thromb Haemost 20 : 888-898, 2022.
 
4) Hosokawa K, Abe K, Funakoshi K, et al : Long-term outcome of chronic thromboembolic pulmonary hypertension using direct oral anticoagulants and warfarin : a Japanese prospective cohort study. J Thromb Haemost 21 : 2151-2162, 2023.
 
5) Hosokawa K, Watanabe H, Taniguchi Y, et al : A Multicenter, Single-Blind, Randomized, Warfarin-Controlled Trial of Edoxaban in Patients With Chronic Thromboembolic Pulmonary Hypertension : KABUKI Trial. Circulation 149 : 406-409, 2024.
 
6) Madani M, Mayer E, Fadel E, et al : Pulmonary Endarterectomy. Patient Selection, Technical Challenges, and Outcomes. Ann Am Thorac Soc 13 (Suppl 3) : S240-S247, 2016.
 
7) Pepke-Zaba J, Delcroix M, Lang I, et al : Chronic thromboembolic pulmonary hypertension (CTEPH) : results from an international prospective registry. Circulation 124 : 1973-1981, 2011.
 
8) Galie N, Kim NHS : Pulmonary microvascular disease in chronic thromboembolic pulmonary hypertension. Proc Am Thorac Soc 3 : 571-576, 2006.
 
9) Ghofrani HA, D'Armini AM, Grimminger F, et al : Riociguat for the treatment of chronic thromboembolic pulmonary hypertension. N Engl J Med 369 : 319-329, 2013.
 
10) Simonneau G, D'Armini AM, Ghofrani HA, et al : Predictors of long-term outcomes in patients treated with riociguat for chronic thromboembolic pulmonary hypertension : data from the CHEST-2 open-label, randomised, long-term extension trial. Lancet Respir Med 4 : 372-380, 2016.
 
11) Ogo T, Shimokawahara H, Kinoshita H, et al : Selexipag for the treatment of chronic thromboembolic pulmonary hypertension. Eur Respir J 60 : 2101694, 2022.
 
12) Feinstein JA, Goldhaber SZ, Lock JE, et al : Balloon pulmonary angioplasty for treatment of chronic thromboembolic pulmonary hypertension. Circulation 103 : 10-13, 2001.
 
13) Sugimura K, Fukumoto Y, Satoh K, et al : Percutaneous transluminal pulmonary angioplasty markedly improves pulmonary hemodynamics and long-term prognosis in patients with chronic thromboembolic pulmonary hypertension. Circ J 76 : 485-488, 2012.
 
14) Mizoguchi H, Ogawa A, Munemasa M, et al : Refined balloon pulmonary angioplasty for inoperable patients with chronic thromboembolic pulmonary hypertension. Circ Cardiovasc Interv 5 : 748-755, 2012.
 
15) Inami T, Kataoka M, Shimura N, et al : Pressure-wire-guided percutaneous transluminal pulmonary angioplasty : a breakthrough in catheter-interventional therapy for chronic thromboembolic pulmonary hypertension. JACC Cardiovasc Interv 7 : 1297-1306, 2014.
 
16) Aoki T, Sugimura K, Tatebe S, et al : Comprehensive evaluation of the effectiveness and safety of balloon pulmonary angioplasty for inoperable chronic thrombo-embolic pulmonary hypertension : long-term effects and procedure-related complications. Eur Heart J 38 : 3152-3159, 2017.
 
17) Ogawa A, Satoh T, Fukuda T, et al : Balloon Pulmonary Angioplasty for Chronic Thromboembolic Pulmonary Hypertension : Results of a Multicenter Registry. Circ Cardiovasc Qual Outcomes 10 : e004029, 2017.
 
18) Wiedenroth CB, Liebetrau C, Breithecker A, et al : Combined pulmonary endarterectomy and balloon pulmonary angioplasty in patients with chronic thromboembolic pulmonary hypertension. J Heart Lung Transplant 35 : 591-596, 2016.
 
19) Aoki T, Sugimura K, Terui Y, et al : Beneficial effects of riociguat on hemodynamic responses to exercise in CTEPH patients after balloon pulmonary angioplasty-A randomized controlled study. Int J Cardiol Heart Vasc 29 : 100579, 2020.
 
20) 日本循環器学会, 日本肺高血圧・肺循環学会, 日本呼吸器学会, ほか : 肺高血圧症治療ガイドライン (2017年改訂版), 2018. [https://www.j-circ.or.jp/cms/wp-content/uploads/2017/10/JCS2017_fukuda_h.pdf] (2024年7月閲覧)
 
21) Kawakami T, Matsubara H, Shinke T, et al : Balloon pulmonary angioplasty versus riociguat in inoperable chronic thromboembolic pulmonary hypertension (MR BPA) : an open-label, randomised controlled trial. Lancet Respir Med 10 : 949-960, 2022.
 
22) Jais X, Brenot P, Bouvaist H, et al : Balloon pulmonary angioplasty versus riociguat for the treatment of inoperable chronic thromboembolic pulmonary hypertension (RACE) : a multicentre, phase 3, open-label, randomised controlled trial and ancillary follow-up study. Lancet Respir Med 10 : 961-971, 2022.
 
P.148 掲載の参考文献
1) Humbert M, Kovacs G, Hoeper MM, et al : 2022 ESC/ERS Guidelines for the diagnosis and treatment of pulmonary hypertension. Eur Heart J 43 : 3618-3731, 2022.
PubMed
2) Lau EM, Manes A, Celermajer DS, et al : Early detection of pulmonary vascular disease in pulmonary arterial hypertension : time to move forward. Eur Heart J 32 : 2489-2498, 2011.
 
3) Nakamura K, Shimizu J, Kataoka N, et al : Altered nano/micro-order elasticity of pulmonary artery smooth muscle cells of patients with idiopathic pulmonary arterial hypertension. Int J Cardiol 140 : 102-107, 2010.
 
4) Krowka MJ, Fallon MB, Kawut SM, et al : International Liver Transplant Society Practice Guidelines : Diagnosis and Management of Hepatopulmonary Syndrome and Portopulmonary Hypertension. Transplantation 100 : 1440-1452, 2016.
 
5) Ward JP, Knock GA, Snetkov VA, et al : Protein kinases in vascular smooth muscle tone-role in the pulmonary vasculature and hypoxic pulmonary vasoconstriction. Pharmacol Ther 104 : 207-231, 2004.
 
6) Henno P, Boitiaux JF, Douvry B, et al : Tobacco-associated pulmonary vascular dysfunction in smokers : role of the ET-1 pathway. Am J Physiol Lung Cell Mol Physiol 300 : L831-L839, 2011.
 
P.156 掲載の参考文献
1) 肺高血圧症治療ガイドライン (2017年改訂版), 日本循環器学会, 2018. [https://www.j-circ.or.jp/cms/wp-content/uploads/2017/10/JCS2017_fukuda_h.pdf] (2024年6月閲覧)
 
2) Humbert M, Kovacs G, Hoeper MM, et al : 2022 ESC/ERS Guidelines for the diagnosis and treatment of pulmonary hypertension. Eur Heart J 43 : 3618-3731, 2022.
PubMed
3) Armstrong I, Billings C, Kiely DG, et al : The patient experience of pulmonary hypertension : a large cross-sectional study of UK patients. BMC Pulm Med 19 : 67, 2019.
 
4) Strange G, Gabbay E, Kermeen F, et al : Time from symptoms to definitive diagnosis of idiopathic pulmonary arterial hypertension : The delay study. Pulm Circ 3 : 89-94, 2013.
 
5) Harjola VP, Mebazaa A, Celutkiene J, et al : Contemporary management of acute right ventricular failure : a statement from the Heart Failure Association and the Working Group on Pulmonary Circulation and Right Ventricular Function of the European Society of Cardiology. Eur J Heart Fail 18 : 226-241, 2016.
 
6) 2021年改訂版 循環器超音波検査の適応と判読ガイドライン, 日本循環器学会, 2021. [https://www.j-circ.or.jp/cms/wp-content/uploads/2021/03/JCS2021_Ohte.pdf] (2024年6月閲覧)
 
7) Kovacs G, Berghold A, Scheidl S, et al : Pulmonary arterial pressure during rest and exercise in healthy subjects : a systematic review. Eur Respir J 34 : 888-894, 2009.
 
8) Sitbon O, Humbert M, Jais X, et al : Long-term response to calcium channel blockers in idiopathic pulmonary arterial hypertension. Circulation 111 : 3105-3111, 2005.
 
9) Remy-Jardin M, Ryerson CJ, Schiebler ML, et al : Imaging of pulmonary hypertension in adults : a position paper from the Fleischner Society. Eur Respir J 57 : 2004455, 2021.
 
10) Tunariu N, Gibbs SJ, Win Z, et al : Ventilation-perfusion scintigraphy is more sensitive than multidetector CTPA in detecting chronic thromboembolic pulmonary disease as a treatable cause of pulmonary hypertension. J Nucl Med 48 : 680-684, 2007.
 
11) He J, Fang W, Lv B, et al : Diagnosis of chronic thromboembolic pulmonary hypertension : comparison of ventilation/perfusion scanning and multidetector computed tomography pulmonary angiography with pulmonary angiography. Nucl Med Commun 33 : 459-463, 2012.
 
P.162 掲載の参考文献
1) Fukuda K, Date H, Doi S, et al : Guidelines for the Treatment of Pulmonary Hypertension (JCS 2017/JPCPHS 2017). Circ J 83 : 842-945, 2019.
 
2) Hoeper MM, Badesch DB, Ghofrani HA, et al : Phase 3 Trial of Sotatercept for Treatment of Pulmonary Arterial Hypertension. N Engl J Med 388 : 1478-1490, 2023.
 
3) Miura Y, Fukumoto Y, Sugimura K, et al : Identification of new prognostic factors of pulmonary hypertension. Circ J 74 : 1965-1971, 2010.
 
4) Hoeper MM, Pausch C, Grunig E, et al : Idiopathic pulmonary arterial hypertension phenotypes determined by cluster analysis from the COMPERA registry. J Heart Lung Transplant 39 : 1435-1444, 2020.
 
5) Humbert M, Kovacs G, Hoeper MM, et al : 2022 ESC/ERS Guidelines for the diagnosis and treatment of pulmonary hypertension. Eur Heart J 43 : 3618-3731, 2022.
PubMed
6) Opitz CF, Hoeper MM, Gibbs JS, et al : Pre-Capillary, Combined, and Post-Capillary Pulmonary Hypertension : A Pathophysiological Continuum. J Am Coll Cardiol 68 : 368-378, 2016.
 
7) McLaughlin VV, Vachiery JL, Oudiz RJ, et al : Patients with pulmonary arterial hypertension with and without cardiovascular risk factors : Results from the AMBITION trial. J Heart Lung Transplant 38 : 1286-1295, 2019.
 
8) Lewis RA, Thompson AAR, Billings CG, et al : Mild parenchymal lung disease and/or low diffusion capacity impacts survival and treatment response in patients diagnosed with idiopathic pulmonary arterial hypertension. Eur Respir J 55 : 2000041, 2020.
 
9) Rosenkranz S, Channick R, Chin KM, et al : The impact of comorbidities on selexipag treatment effect in patients with pulmonary arterial hypertension : insights from the GRIPHON study. Eur J Heart Fail 24 : 205-214, 2022.
 
10) D'Alto M, Badagliacca R, Argiento P, et al : Risk Reduction and Right Heart Reverse Remodeling by Upfront Triple Combination Therapy in Pulmonary Arterial Hypertension. Chest 157 : 376-383, 2020.
 
P.166 掲載の参考文献
1) Jabbari M, Cherry R, Lough JO, et al : Gastric antral vascular ectasia : the watermelon stomach. Gastroenterology 87 : 1165-1170, 1984.
 
2) Sebastian S, O'Morain CA, Buckley MJ : Review article : current therapeutic options for gastric antral vascular ectasia. Aliment Pharmacol Ther 18 : 157-165, 2003.
 
3) Gostout CJ, Viggiano TR, Ahlquist DA, et al : The clinical and endoscopic spectrum of the watermelon stomach. J Clin Gastroenterol 15 : 256-263, 1992.
 
4) 岩本淳一, 小西直樹, 柿崎文郎, ほか : 胃幽門前庭部血管拡張症 (GAVE), 胃血管拡張症. 消化器内視鏡 33 : 57-60, 2021.
 
5) Lorenzi AR, Johnson AH, Davies G, et al : Gastric antral vascular ectasia in systemic sclerosis : complete resolution with methylprednisolone and cyclophosphamide. Ann Rheum Dis 60 : 796-798, 2001.
 
6) Harrison DF : Use of estrogen in treatment of familial hemorrhagic telangiectasia. Laryngoscope 92 : 314-320, 1982.
 
7) van Cutsem E, Rutgeerts P, Vantrappen G : Treatment of bleeding gastrointestinal vascular malformations with oestrogen-progesterone. Lancet 335 : 953-955, 1990.
 
8) Manning RJ : Estrogen/progesterone treatment of diffuse antral vascular ectasia. Am J Gastroenterol 90 : 154-156, 1995.
 
9) Park RH, Danesh BJ, Upadhyay R, et al : Gastric antral vascular ectasia (watermelon stomach) -therapeutic options. Postgrad Med J 66 : 720-723, 1990.
 
10) Dunne KA, Hill J, Dillon JF : Treatment of chronic transfusion-dependent gastric antral vascular ectasia (watermelon stomach) with thalidomide. Eur J Gastroenterol Hepatol 18 : 455-456, 2006.
 
11) Bhatti MA, Khan AA, Alam A, et al : Efficacy of argon plasma coagulation in gastric vascular ectasia in patients with liver cirrhosis. J Coll Physicians Surg Pak 19 : 219-222, 2009.
 
12) Lecleire S, Ben-Soussan E, Antonietti M, et al : Bleeding gastric vascular ectasia treated by argon plasma coagulation : a comparison between patients with and without cirrhosis. Gastrointest Endosc 67 : 219-225, 2008.
 
13) 中村真一, 光永篤, 小西洋之, ほか : アルゴンプラズマ凝固法で治療した胃前庭部毛細血管拡張症の長期経過. 日本消化器内視鏡学会雑誌 50 : 1495-1502, 2008.
 
14) Mohan BP, Toy G, Kassab LL, et al : Endoscopic band ligation in the treatment of gastric antral vascular ectasia : a systematic review and meta-analysis. Gastrointest Endosc 94 : 1021-1029.e10, 2021.
 
P.172 掲載の参考文献
1) 増補版 遺伝性出血性末梢血管拡張症 (オスラー病 ; HHT) の診療マニュアル (塩谷隆信編), p1-175, 中外医学社, 2015.
 
2) Faughnan ME, Mager JJ, Hetts SW, et al : Second International Guidelines for the Diagnosis and Management of Hereditary Hemorrhagic Telangiectasia. Ann Intern Med 173 : 989-1001, 2020.
 
3) Al-Samkari H : Systemic Antiangiogenic Therapies for Bleeding in Hereditary Hemorrhagic Telangiectasia : A Practical, Evidence-Based Guide for Clinicians. Semin Thromb Hemost 48 : 514-528, 2022.
 
4) Zaffar N, Ravichakaravarthy T, Faughnan ME, et al : The use of anti-fibrinolytic agents in patients with HHT : a retrospective survey. Ann Hematol 94 : 145-152, 2015.
 
5) Al-Samkari H, Kasthuri RS, Parambil JG, et al : An international, multicenter study of intravenous bevacizumab for bleeding in hereditary hemorrhagic telangiectasia : the InHIBIT-Bleed study. Haematologica 106 : 2161-2169, 2021.
 
6) Parambil JG, Gossage JR, McCrae KR, et al : Pazopanib for severe bleeding and transfusion-dependent anemia in hereditary hemorrhagic telangiectasia. Angiogenesis 25 : 87-97, 2022.
 
7) Buscarini E, Botella LM, Geisthoff U, et al : Safety of thalidomide and bevacizumab in patients with hereditary hemorrhagic telangiectasia. Orphanet J Rare Dis 14 : 28, 2019.
 
8) Harrison L, Kundra A, Jervis P : The use of thalidomide therapy for refractory epistaxis in hereditary haemorrhagic telangiectasia : systematic review. J Laryngol Otol 132 : 866-871, 2018.
 
P.176 掲載の参考文献
1) Kanth R, Mali P, Roy PK : Outcomes in Dieulafoy's Lesion : A 10-Year Clinical Review. Dig Dis Sci 60 : 2097-2103, 2015.
 
2) Lee YT, Walmsley RS, Leong RW, et al : Dieulafoy's lesion. Gastrointest Endosc 58 : 236-243, 2003.
 
3) Baxter M, Aly EH : Dieulafoy's lesion : current trends in diagnosis and management. Ann R Coll Surg Engl 92 : 548-554, 2010.
PubMed
4) Chaer RA, Helton WS : Dieulafoy's disease. J Am Coll Surg 196 : 290-296, 2003.
 
5) Lara LF, Sreenarasimhaiah J, Tang SJ, et al : Dieulafoy lesions of the GI tract : localization and therapeutic outcomes. Dig Dis Sci 55 : 3436-3441, 2010.
 
6) Norton ID, Petersen BT, Sorbi D, et al : Management and long-term prognosis of Dieulafoy lesion. Gastrointest Endosc 50 : 762-767, 1999.
 
7) Wang Y, Bansal P, Li S, et al : Dieulafoy's lesion of the upper GI tract : a comprehensive nationwide database analysis. Gastrointest Endosc 94 : 24-34.e5, 2021.
 
8) Wright CA, Petersen BT, Bridges CM, et al : Heparin provocation for identification and treatment of a gastric Dieulafoy's lesion. Gastrointest Endosc 59 : 728-730, 2004.
 
9) Ryan JM, Key SM, Dumbleton SA, et al : Nonlocalized lower gastrointestinal bleeding : provocative bleeding studies with intraarterial tPA, heparin, and tolazoline. J Vasc Interv Radiol 12 : 1273-1277, 2001.
 
10) Batouli A, Kazemi A, Hartman MS, et al : Dieulafoy lesion : CT diagnosis of this lesser-known cause of gastrointestinal bleeding. Clin Radiol 70 : 661-666, 2015.
 
11) Mansfield G, Sabharwal R, Bansi DS, et al : Dieulafoy lesions : rare but often overdiagnosed? Observations based upon a case of small bowel haemorrhage and a critical review of the literature. Clin Radiol 67 : 78-80, 2012.
 
12) Yamaguchi Y, Yamato T, Katsumi N, et al : Short-term and long-term benefits of endoscopic hemoclip application for Dieulafoy's lesion in the upper GI tract. Gastrointest Endosc 57 : 653-656, 2003.
 
13) Chung IK, Kim EJ, Lee MS, et al : Bleeding Dieulafoy's lesions and the choice of endoscopic method : comparing the hemostatic efficacy of mechanical and injection methods. Gastrointest Endosc 52 : 721-724, 2000.
 
P.180 掲載の参考文献
1) Kaijser R : Uber Hamangiome des Tractus gastrointestinalis. Arch Klin Chir 187 : 351-388, 1936.
 
2) Moore JD, Thompson NW, Appelman HD, et al : Arteriovenous malformations of the gastrointestinal tract. Arch Surg 111 : 381-389, 1976.
 
3) Gentry RW, Dockerty MB, Glagett OT : Vascular malformations and vascular tumors of the gastrointestinal tract. Surg Gynecol Obstet 88 : 281-323, 1949.
 
4) Margulis AR, Heinbecker P, Bernard HR : Operative mesenteric arteriography in the search for the site of bleeding in unexplained gastrointestinal hemorrhage : a preliminary report. Surgery 48 : 534-539, 1960.
 
5) Richardson JD : Vascular lesions of the intestines. Am J Surg 161 : 284-293, 1991.
 
6) Boley SJ, Sammartano R, Adams A, et al : On the nature and etiology of vascular ectasias of the colon. Degenerative lesions of aging. Gastroenterology 72 : 650-660, 1977.
 
7) Heyde EC : Gastrointestinal bleeding in aortic stenosis (Letter). N Engl J Med 259 : 196, 1958.
 
8) 宮崎亮佑, 猿田雅之 : 胃動静脈奇形 (AVM). 日本臨牀 75 (増刊 : 動脈・静脈の疾患 (下)) : 835-840, 2017.
 
9) Kojima Y, Takeuchi T, Egashira Y, et al : Endoscopic Submucosal Dissection for Gastric Arteriovenous Malformation. Intern Med 55 : 3221-3223, 2016.
 
P.184 掲載の参考文献
1) Bjorck M, Koelemay M, Acosta S, et al : Editor's Choice-Management of the Diseases of Mesenteric Arteries and Veins : Clinical Practice Guidelines of the European Society of Vascular Surgery (ESVS). Eur J Vasc Endovasc Surg 53 : 460-510, 2017.
 
2) Karmody AM, Jordan FR, Zaman SN : Left colon gangrene after acute inferior mesenteric artery occlusion. Arch Surg 111 : 972-975, 1976.
 
3) 平野昌孝, 西沢佑次郎, 鈴木謙, ほか : 急性腸間膜動脈閉塞症. 臨床外科 77 : 178-182, 2022.
 
4) Kassahun WT, Schulz T, Richter O, et al : Unchanged high mortality rates from acute occlusive intestinal ischemia : six year review. Langenbecks Arch Surg 393 : 163-171, 2008.
 
5) 小山文一, 錦織直人, 中島祥介 : 急性腸間膜動脈閉塞症. 日本臨牀 75 (増刊 : 動脈・静脈の疾患 (下)) : 845-849, 2017.
 
6) 木下光博 : 上腸間膜動脈閉塞症. レジデントノート 23 : 836-841, 2021.
 
7) 松原健太郎, 尾原秀明, 北川雄光 : 腹部大動脈, 上腸間膜動脈の血栓・塞栓症の診断と治療. 日本臨牀 72 : 1289-1293, 2014.
 
8) 井上芳徳 : 急性上腸間膜動脈閉塞症の手術手技. 手術 67 : 311-314, 2013.
 
9) 天野邦彦, 山本瑛介, 石田秀行 : 小腸大量切除術 (SMA閉塞症を中心に). 臨床外科 74 : 142-146, 2019.
 
10) 吉田有佑, 信久徹治, 藤本卓也, ほか : インドシアニングリーン (ICG) 蛍光法を利用した急性上腸間膜動脈閉塞症の3例. 外科 81 : 897-902, 2019.
 
11) 三輪光春 : ICG螢光法による光生体計測. 医学のあゆみ 232 : 1298-1300, 2010.
 
12) Beaulieu RJ, Arnaoutakis KD, Abularrage CJ, et al : Comparison of open and endovascular treatment of acute mesenteric ischemia. J Vasc Surg 59 : 159-164, 2014.
 
13) 菅野範英 : 消化管慢性腸間膜動脈閉塞症. 日本臨牀 75 (増刊 : 動脈・静脈の疾患 (下)) : 850-854, 2017.
 
14) 古森公浩 : 上腸間膜動脈閉塞症. 成人病と生活習慣病 47 : 1524-1528, 2017.
 
15) Resch T, Lindh M, Dias N, et al : Endovascular recanalisation in occlusive mesenteric ischemia-feasibility and early results. Eur J Vasc Endovasc Surg 29 : 199-203, 2005.
 
P.191 掲載の参考文献
1) 岩下明徳, 竹村聡, 長谷川修三, ほか : 原因別にみた虚血性腸病変の病理形態. 胃と腸 28 : 927-941, 1993.
 
2) Yao T, Iwashita A, Hoashi T, et al : Phlebosclerotic colitis : value of radiography in diagnosis-report of three cases. Radiology 214 : 188-192, 2000.
 
3) Iwashita A, Yao T, Schlemper RJ, et al : Mesenteric phlebosclerosis : a new disease entity causing ischemic colitis. Dis Colon Rectum 46 : 209-220, 2003.
 
4) 吉永繁高, 中村和彦, 原田直彦, ほか : 特発性腸間膜静脈硬化症の臨床-臨床像. 胃と腸 44 : 163-169, 2009.
 
5) Chang KM : New histologic findings in idiopathic mesenteric phlebosclerosis : clues to its pathogenesis and etiology-probably ingested toxic agent-related. J Chin Med Assoc 70 : 227-235, 2007.
 
6) Hiramatsu K, Sakata H, Horita Y, et al : Mesenteric phlebosclerosis associated with long-term oral intake of geniposide, an ingredient of herbal medicine. Aliment Pharmacol Ther 36 : 575-586, 2012.
 
7) 大津健聖, 松井敏幸, 西村拓, ほか : 漢方薬内服により発症した腸間膜静脈硬化症の臨床経過. 日本消化器病学会雑誌 111 : 61-68, 2014.
 
8) Shimizu S, Kobayashi T, Tomioka H, et al : Involvement of herbal medicine as a cause of mesenteric phlebosclerosis : results from a large-scale nationwide survey. J Gastroenterol 52 : 308-314, 2017.
 
9) Nagata Y, Watanabe T, Nagasaka K, et al : Total dosage of gardenia fruit used by patients with mesenteric phlebosclerosis. BMC Complement Altern Med 16 : 207, 2016.
 
10) 三輪亘, 平塚卓, 神谷雄介, ほか : 発症から漢方薬服薬中止により改善まで7年間の経過観察が可能であった腸間膜静脈硬化症の1例. 日本消化器内視鏡学会雑誌 57 : 1278-1283, 2015.
 
11) 清水誠治 : 最近注目されている腸の炎症性疾患 IV. 腸間膜静脈硬化症. 日本大腸肛門病学会雑誌 74 : 606-612, 2021.
 
12) 中沢和之, 新垣直樹, 前北隆雄, ほか : アスピリンとワルファリンの併用療法が有効と考えられた特発性腸間膜静脈硬化症の1例. 日本消化器内視鏡学会雑誌 58 : 2169-2175, 2016.
 
13) 清水誠治, 富岡秀夫, 石田英和, ほか : 腸間膜静脈硬化症における漢方薬中止後の病像変化. 胃と腸 51 : 483-490, 2016.
 
14) 日比紀文, 松井敏幸, 清水誠治, ほか : 腸間膜静脈硬化症-発症の実態と予後-. Progress in Medicine 38 : 175-182, 2018.
 
15) Kawasaki K, Eizuka M, Kudara N, et al : Mesenteric phlebosclerosis complicating colonic cancer treated by endoscopic submucosal dissection. Clin J Gastroenterol 13 : 1183-1188, 2020.
 
P.197 掲載の参考文献
1) Dai C, Liu WX, Jiang M, et al : Endoscopic variceal ligation compared with endoscopic injection sclerotherapy for treatment of esophageal variceal hemorrhage : a meta-analysis. World J Gastroenterol 21 : 2534-2541, 2015.
 
2) Drolz A, Schramm C, Seiz O, et al : Risk factors associated with bleeding after prophylactic endoscopic variceal ligation in cirrhosis. Endoscopy 53 : 226-234, 2021.
 
3) Wang J, Chen S, Naga YM, et al : Esophageal Variceal Ligation Monotherapy versus Combined Ligation and Sclerotherapy for the Treatment of Esophageal Varices. Can J Gastroenterol Hepatol 2021 : 8856048, 2021.
 
4) Miyamoto S, Yamamoto Y, Takagi T : New method of endoscopic injection sclerosis for esophageal varices using by modified endoscopic hood. Dig Endosc 32 : e82-e83, 2020.
 
5) Furuichi Y, Abe M, Kasai Y, et al : Secure intravariceal sclerotherapy with red dichromatic imaging decreases the recurrence rate of esophageal varices : A propensity score matching analysis. J Hepatobiliary Pancreat Sci 28 : 431-442, 2021.
 
6) Ishikawa T, Sasaki R, Nishimura T, et al : Splenic non-infarction volume determines a clinically significant hepatic venous pressure gradient response to partial splenic embolization in patients with cirrhosis and hypersplenism. J Gastroenterol 56 : 382-394, 2021.
 
7) Ishikawa T, Sasaki R, Nishimura T, et al : A novel therapeutic strategy for esophageal varices using endoscopic treatment combined with splenic artery embolization according to the Child-Pugh classification. PLoS One 14 : e0223153, 2019.
 
8) Iwase H, Shimada M, Tsuzuki T, et al : Long-term results of endoscopic obliteration with cyanoacrylate glue for gastric fundal variceal bleeding : a 17-year experience. Japanese Journal of Portal Hypertension 17 : 137-144, 2011.
 
9) Gwon DI, Ko GY, Yoon HK, et al : Gastric varices and hepatic encephalopathy : treatment with vascular plug and gelatin sponge-assisted retrograde transvenous obliteration-a primary report. Radiology 268 : 281-287, 2013.
 
10) Lee EW, Saab S, Gomes AS, et al : Coil-Assisted Retrograde Transvenous Obliteration (CARTO) for the Treatment of Portal Hypertensive Variceal Bleeding : Preliminary Results. Clin Transl Gastroenterol 5 : e61, 2014.
 
11) Shreve L, Lee EW : Role of Interventional Radiology in Complications of Portal Hypertension. J Clin Gastroenterol 53 : 342-349, 2019.
 
12) Kobayakawa M, Ohnishi S, Suzuki H : Recent development of balloon-occluded retrograde transvenous obliteration. J Gastroenterol Hepatol 34 : 495-500, 2019.
 
13) Irisawa A, Shibukawa G, Hoshi K, et al : Endoscopic ultrasound-guided coil deployment with sclerotherapy for isolated gastric varices : Case series of feasibility, safety, and long-term follow-up. Dig Endosc 32 : 1100-1104, 2020.
 
14) Robles-Medranda C, Oleas R, Valero M, et al : Endoscopic ultrasonography-guided deployment of embolization coils and cyanoacrylate injection in gastric varices versus coiling alone : a randomized trial. Endoscopy 52 : 268-275, 2020.
 
15) 門脈圧亢進症の診療ガイド 2022 (日本肝臓学会・日本門脈圧亢進症学会編), 文光堂, 2022.
 
P.204 掲載の参考文献
1) Thomson WH : The nature of haemorrhoids. Br J Surg 62 : 542-552, 1975.
 
2) Haas PA, Fox TA Jr, Haas GP : The pathogenesis of hemorrhoids. Dis Colon Rectum 27 : 442-450, 1984.
 
3) 大堀晃裕 : 痔核の病因と臨床病理学的研究. 東邦医学会雑誌 43 : 139-148, 1996.
 
4) Voderholzer WA, Schatke W, Muhldorfer BE, et al : Clinical response to dietary fiber treatment of chronic constipation. Am J Gastroenterol 92 : 95-98, 1997.
 
5) Del Piano M, Carmagnola S, Anderloni A, et al : The use of probiotics in healthy volunteers with vacuation disorders and hard stools : a double-blind, randomized, placebo-controlled study. J Clin Gastroenterol 44 (Suppl 1) : S30-34, 2010.
 
6) Ishizuka A, Tomizuka K, Aoki R, et al : Effects of administration of Bifidobacterium animalis subsp. lactis GCL2505 on defecation frequency and bifidobacterial microbiota composition in humans. J Biosci Bioeng 113 : 587-591, 2012.
 
7) Takano M, Iwadare J, Ohba H, et al : Sclerosing therapy of internal hemorrhoids with a novel sclerosing agent. Comparison with ligation and excision. Int J Colorectal Dis 21 : 44-51, 2006.
 
8) Milligan ETC, Morgan CN, Naunton J, et al : Surgical anatomy of the anal canal and operative treatment of haemorrhoids. Lancet 2 : 1119-1124, 1937.
 
9) Ferguson JA, Heaton JR : Closed hemorrhoidectomy. Dis Colon Rectum 2 : 176-179, 1959.
PubMed
10) Takano M : Anoderm-preserving hemorrhoidectomy. Dis Colon Rectum 23 : 544-549, 1980.
 
11) Mikuni N, Oya M, Komatsu J, et al : A prospective randomized comparison between an open hemorrhoidectomy and a semi-closed (semi-open) hemorrhoidectomy. Surg Today 32 : 40-47, 2002.
 
12) Longo A : Treatment of hemorrhoids disease by reduction of mucosa and hemorrhoidal prolapse with a circular suturing device : a new procedure. Proceedings of the 6th World Congress of Endoscopic Surgery, p777-784, Mundozzi Editore, Rome, 1998.
 
13) Cheetham MJ, Mortensen NJ, Nystrom PO, et al : Persistent pain and faecal urgency after stapled haemorrhoidectomy. Lancet 356 : 730-733, 2000.
 
14) 梅枝覚, 松本好市, 北川達士, ほか : 痔核治療におけるPPHの役割-その適応とメリット・デメリット LEやALTAとの比較におけるPPHの適応や長所短所. 日本大腸肛門病会誌 63 : 838-845, 2010.
 
15) Abe T, Hachiro Y, Ebisawa Y, et al : Distal hemorrhoidectomy with ALTA injection : a new method for hemorrhoid surgery. Int Surg 99 : 295-298, 2014.
 
P.210 掲載の参考文献
1) de Mast Q, Beutler JJ : The prevalence of atherosclerotic renal artery stenosis in risk groups : a systematic literature review. J Hypertens 27 : 1333-1340, 2009.
PubMed
2) Carmichael DJ, Mathias CJ, Snell ME, et al : Detection and investigation of renal artery stenosis. Lancet 1 : 667-670, 1986.
 
3) Terminology and Diagnostic Criteria Committee, Japan Society of Ultrasonics in Medicine : Standard method for ultrasound evaluation of renal arterial lesions. J Med Ultrason (2001) 43 : 145-162, 2016.
 
4) Stacul F, Gava S, Belgrano M, et al : Renal artery stenosis : comparative evaluation of gadolinium-enhanced MRA and DSA. Radiol Med 113 : 529-546, 2008.
 
5) Wilcox CS : Use of angiotensin-converting-enzyme inhibitors for diagnosing renovascular hypertension. Kidney Int 44 : 1379-1390, 1993.
PubMed
6) Losito A, Errico R, Santirosi P, et al : Long-term follow-up of atherosclerotic renovascular disease. Beneficial effect of ACE inhibition. Nephrol Dial Transplant 20 : 1604-1609, 2005.
 
7) Iwasaki T, Mishima E, Suzuki T, et al : Kidney enlargement effect of angioplasty for nonatherosclerotic renovascular disease : reversibility of ischemic kidney. Hypertens Res 43 : 1214-1221, 2020.
 
8) Gornik HL, Persu A, Adlam D, et al : First International Consensus on the diagnosis and management of fibromuscular dysplasia. Vasc Med 24 : 164-189, 2019.
 
9) Oribe S, Toyohara T, Mishima E, et al : Fibromuscular dysplasia with recurrence after "long-term" following percutaneous transcatheter renal angioplasty : two case reports with a review of 26 patients. BMC Nephrol 22 : 187, 2021.
 
10) Chrysant SG : The current status of angioplasty of atherosclerotic renal artery stenosis for the treatment of hypertension. J Clin Hypertens (Greenwich) 15 : 694-698, 2013.
 
11) Textor SC, McKusick MM, Misra S, et al : Timing and selection for renal revascularization in an era of negative trials : what to do? Prog Cardiovasc Dis 52 : 220-228, 2009.
 
12) Fujihara M, Yokoi Y, Abe T, et al : Clinical outcome of renal artery stenting for hypertension and chronic kidney disease up to 12 months in the J-RAS Study-prospective, single-arm, multicenter clinical study. Circ J 79 : 351-359, 2015.
 
13) Murphy TP, Cooper CJ, Pencina KM, et al : Relationship of Albuminuria and Renal Artery Stent Outcomes : Results From the CORAL Randomized Clinical Trial (Cardiovascular Outcomes With Renal Artery Lesions). Hypertension 68 : 1145-1152, 2016.
 
14) Abe M, Araya K, Akaishi T, et al : Long-term assessment of intrarenal blood flow with Doppler ultrasonography for hypertensive patients after percutaneous transluminal renal angioplasty. Hypertens Res 42 : 1649-1651, 2019.
 
15) Aboyans V, Ricco JB, Bartelink MEL, et al : 2017 ESC Guidelines on the Diagnosis and Treatment of Peripheral Arterial Diseases, in collaboration with the European Society for Vascular Surgery (ESVS) : Document covering atherosclerotic disease of extracranial carotid and vertebral, mesenteric, renal, upper and lower extremity arteriesEndorsed by : the European Stroke Organization (ESO) The Task Force for the Diagnosis and Treatment of Peripheral Arterial Diseases of the European Society of Cardiology (ESC) and of the European Society for Vascular Surgery (ESVS). Eur Heart J 39 : 763-816, 2018.
 
P.218 掲載の参考文献
1) Huang CC, Lo HC, Huang HH, et al : ED presentations of acute renal infarction. Am J Emerg Med 25 : 164-169, 2007.
 
2) Nagasawa T, Matsuda K, Takeuchi Y, et al : A case series of acute renal infarction at a single center in Japan. Clin Exp Nephrol 20 : 411-415, 2016.
 
3) Hoxie HJ, Coggin CB : Renal Infarction : Statistical study of two hundred and five cases and detailed report of an unusual case. Arch Intern Med 65 : 587-594, 1940.
 
4) Oh YK, Yang CW, Kim YL, et al : Clinical Characteristics and Outcomes of Renal Infarction. Am J Kidney Dis 67 : 243-250, 2016.
 
5) Faucon AL, Bobrie G, Jannot AS, et al : Cause of renal infarction : a retrospective analysis of 186 consecutive cases. J Hypertens 36 : 634-640, 2018.
 
6) Bae EJ, Hwang K, Jang HN, et al : A retrospective study of short- and long-term effects on renal function after acute renal infarction. Ren Fail 36 : 1385-1389, 2014.
 
7) Bourgault M, Grimbert P, Verret C, et al : Acute renal infarction : a case series. Clin J Am Soc Nephrol 8 : 392-398, 2013.
 
8) Frost L, Engholm G, Johnsen S, et al : Incident thromboembolism in the aorta and the renal, mesenteric, pelvic, and extremity arteries after discharge from the hospital with a diagnosis of atrial fibrillation. Arch Intern Med 161 : 272-276, 2001.
 
9) Hazanov N, Somin M, Attali M, et al : Acute renal embolism. Forty-four cases of renal infarction in patients with atrial fibrillation. Medicine (Baltimore) 83 : 292-299, 2004.
 
10) Bemanian S, Motallebi M, Nosrati SM : Cocaine-induced renal infarction : report of a case and review of the literature. BMC Nephrol 6 : 10, 2005.
 
11) Hoefsloot W, de Vries RA, Bruijnen R, et al : Renal infarction after cocaine abuse : a case report and review. Clin Nephrol 72 : 234-236, 2009.
 
12) Filippone EJ, Foy A, Galanis T, et al : Segmental arterial mediolysis : report of 2 cases and review of the literature. Am J Kidney Dis 58 : 981-987, 2011.
 
13) Golbus SM, Swerdlin AR, Mitas JA 2nd, et al : Renal artery thrombosis in a young woman taking oral contraceptives. Ann Intern Med 90 : 939-940, 1979.
 
14) Slick GL, Schnetzler DE, Kaloyanides GJ : Hypertension, renal vein thrombosis and renal failure (occurring in a patient on an oral contraceptive agent). Clin Nephrol 3 : 70-74, 1975.
 
15) Bhargava A, Chopra A, Bernabela L, et al : Oral contraceptive causing renal artery thrombosis. BMJ Case Rep 2013 : bcr2012008055, 2013.
 
16) Post A, den Deurwaarder ESG, Bakker SJL, et al : Kidney Infarction in Patients With COVID-19. Am J Kidney Dis 76 : 431-435, 2020.
 
17) Sardu C, Gambardella J, Morelli MB, et al : Hypertension, Thrombosis, Kidney Failure, and Diabetes : Is COVID-19 an Endothelial Disease? A Comprehensive Evaluation of Clinical and Basic Evidence. J Clin Med 9 : 1417, 2020.
 
18) Ammous A, Ghaffar MA, El-Charabaty E, et al : Renal infarction in COVID-19 patient. J Nephrol 34 : 267-268, 2021.
 
19) Garcia-Garcia A, Demelo-Rodriguez P, Ordieres-Ortega L, et al : Idiopathic versus Provoked Renal Infarction : Characteristics and Long-Term Follow-Up of a Cohort of Patients in a Tertiary Hospital. Kidney Blood Press Res 44 : 1432-1440, 2019.
 
20) Tsai SH, Chu SJ, Chen SJ, et al : Acute renal infarction : a 10-year experience. Int J Clin Pract 61 : 62-67, 2007.
 
21) Antopolsky M, Simanovsky N, Stalnikowicz R, et al : Renal infarction in the ED : 10-year experience and review of the literature. Am J Emerg Med 30 : 1055-1060, 2012.
 
22) Kansal S, Feldman M, Cooksey S, et al : Renal artery embolism : a case report and review. J Gen Intern Med 23 : 644-647, 2008.
 
23) Kim SH, Park JH, Han JK, et al : Infarction of the kidney : role of contrast enhanced MRI. J Comput Assist Tomogr 16 : 924-928, 1992.
 
24) エビデンスに基づくCKD診療ガイドライン 2023 (日本腎臓学会編), 東京医学社, 2023.
 
25) Silverberg D, Menes T, Rimon U, et al : Acute renal artery occlusion : Presentation, treatment, and outcome. J Vasc Surg 64 : 1026-1032, 2016.
 
26) Ouriel K, Andrus CH, Ricotta JJ, et al : Acute renal artery occlusion : when is revascularization justified? J Vasc Surg 5 : 348-355, 1987.
 
27) Blum U, Billmann P, Krause T, et al : Effect of local low-dose thrombolysis on clinical outcome in acute embolic renal artery occlusion. Radiology 189 : 549-554, 1993.
 
28) Salam TA, Lumsden AB, Martin LG : Local infusion of fibrinolytic agents for acute renal artery thromboembolism : report of ten cases. Ann Vasc Surg 7 : 21-26, 1993.
 
29) Karakurt A : New Thrombolytic Infusion Application of Dissolving Renal Artery Embolic Thrombosis : Low-Dose Slow-Infusion Thrombolytic Therapy. Case Rep Nephrol 2018 : 1609025, 2018.
 
30) Paris B, Bobrie G, Rossignol P, et al : Blood pressure and renal outcomes in patients with kidney infarction and hypertension. J Hypertens 24 : 1649-1654, 2006.
 
P.223 掲載の参考文献
1) Nosher JL, Chung J, Brevetti LS, et al : Visceral and renal artery aneurysms : a pictorial essay on endovascular therapy. Radiographics 26 : 1687, 2006.
 
2) Chaer RA, Abularrage CJ, Coleman DM, et al : The Society for Vascular Surgery clinical practice guidelines on the management of visceral aneurysms. J Vasc Surg 72 : 3S-39S, 2020.
 
3) 岡本好生, 吉川和寛 : 腎臓の解剖. 透析ケア 30 : 316-322, 2024.
 
4) Ruggenenti P, Cravedi P, Remuzzi G : Aneurysms of the Renal Artery, and Dissecting Aneurysms of the Renal Artery. In : Brenner & Rector's The Kidney, 10th Edition (ed by Skorecki K, Chertow GM, Marsden PA, et al), p1203-1204, Elsevier, Philadelphia, 2016.
 
5) Tham G, Ekelund L, Herrlin K, et al : Renal artery aneurysms. Natural history and prognosis. Ann Surg 197 : 348-352, 1983.
 
6) Henke PK, Cardneau JD, Welling TH 3rd, et al : Renal artery aneurysms : a 35-year clinical experience with 252 aneurysms in 168 patients. Ann Surg 234 : 454-463, 2001.
 
7) Pasha SF, Gloviczki P, Stanson AW, et al : Splanchnic artery aneurysms. Mayo Clin Proc 82 : 472-479, 2007.
PubMed
8) Roman LI, Efel CF, Franca VT, et al : Renal artery pseudoaneurysm. J Bras Nefrol 39 : 458-461, 2017.
 
9) Klausner JQ, Lawrence PF, Harlander-Locke MP, et al : The contemporary management of renal artery aneurysms. J Vasc Surg 61 : 978-984, 2015.
 
10) Augustin G, Kulis T, Kello N, et al : Ruptured renal artery aneurysm in pregnancy and puerperium : literature review of 53 cases. Arch Gynecol Obstet 299 : 923-931, 2019.
 
11) Richardson AJ, Liddington M, Jaskowski A, et al : Pregnancy in a renal transplant recipient complicated by rupture of a transplant renal artery aneurysm. Br J Surg 77 : 228-229, 1990.
 
12) Kok HK, Asadi H, Sheehan M, et al : Systematic Review and Single-Center Experience for Endovascular Management of Visceral and Renal Artery Aneurysms. J Vasc Interv Radiol 27 : 1630-1641, 2016.
 
13) 重松邦広, 内田敬二, 鬼塚誠二, ほか : 内臓動脈瘤診療に関する米国血管外科学会ポケットガイド日本語訳版. 日本血管外科学会雑誌 32 : 41-50, 2023.
 
14) Olin JW, Gornik HL, Bacharach JM, et al : Fibromuscular dysplasia : state of the science and critical unanswered questions : a scientific statement from the American Heart Association. Circulation 129 : 1048-1078, 2014.
 
P.228 掲載の参考文献
1) Flory CM : Arterial Occlusions Produced by Emboli from Eroded Aortic Atheromatous Plaques. Am J Pathol 21 : 549-565, 1945.
PubMed
2) Scolari F, Tardanico R, Zani R, et al : Cholesterol crystal embolism : A recognizable cause of renal disease. Am J Kidney Dis 36 : 1089-1109, 2000.
 
3) 動脈硬化性疾患予防ガイドライン 2022年版, p39-40, 一般社団法人日本動脈硬化学会, 2022.
 
4) レジデントのための腎臓病診療マニュアル 第3版 (深川雅史, 安田隆編), p426-428, 医学書院, 2017.
 
5) 持田泰寛, 日高寿美, 小林修三 : コレステロール塞栓症. 腎と透析 95 (増刊) : 197-201, 2023.
 
6) Komatsu S, Yutani C, Ohara T, et al : Angioscopic Evaluation of Spontaneously Ruptured Aortic Plaques. J Am Coll Cardiol 71 : 2893-2902, 2018.
PubMed
7) Meyrier A : Cholesterol crystal embolism : diagnosis and treatment. Kidney Int 69 : 1308-1312, 2006.
 
8) Shi C, Kim T, Steiger S, et al : Crystal clots as therapeutic target in cholesterol crystal embolism. Circ Res 126 : e37-e52, 2020.
 
9) Mulay SR, Evan A, Anders HJ : Molecular mechanisms of crystal-related kidney inflammation and injury. Implications for cholesterol embolism, crystalline nephropathies and kidney stone disease. Nephrol Dial Transplant 29 : 507-514, 2014.
 
10) Yang L, Steiger S, Shi C, et al : Both hyperglycemia and hyperuricemia aggravate acute kidney injury during cholesterol embolism syndrome despite opposite effects on kidney infarct size. Kidney Int 104 : 139-150, 2023.
 
11) Fine MJ, Kapoor W, Falanga V : Cholesterol crystal embolization : a review of 221 cases in the English literature. Angiology 38 : 769-784, 1987.
 
12) Scolari F, Ravani P : Atheroembolic renal disease. Lancet 375 : 1650-1660, 2010.
PubMed
13) Bayliss G, Zhuang S : Cholesterol Crystal Embolism and Chronic Kidney Disease. Int J Mol Sci 18 : 1120, 2017.
 
14) Mochida Y, Ohtake T, Ishioka K, et al : Association between eosinophilia and renal prognosis in patients with pathologically proven cholesterol crystal embolism. Clin Exp Nephrol 24 : 680-687, 2020.
 
15) Belenfant X, Meyrier A, Jacquot C : Supportive treatment improves survival in multivisceral cholesterol crystal embolism. Am J Kidney Dis 33 : 840-850, 1999.
 
16) Nakayama M, Izumaru K, Nagata M, et al : The effect of low-dose corticosteroids on short- and long-term renal outcome in patients with cholesterol crystal embolism. Ren Fail 33 : 298-306, 2011.
 
17) 石山勝也 : コレステロール塞栓症に対するLDLアフェレシスの有効性. 日本アフェレシス学会雑誌 42 : 110-115, 2023.
 
18) Tsunoda S, Daimon S, Miyazaki R, et al : LDL apheresis as intensive lipid-lowering therapy for cholesterol embolism. Nephrol Dial Transplant 14 : 1041-1042, 1999.
 
19) Ishiyama K, Sato T, Yamaguchi T, et al : Efficacy of low-density lipoprotein apheresis combined with corticosteroids for cholesterol crystal embolism. Clin Exp Nephrol 21 : 228-235, 2017.
 
20) Ishiyama K, Sato T : Efficacy of LDL apheresis for the treatment of cholesterol crystal embolism : A prospective, controlled study. Ther Apher Dial 26 : 456-464, 2022.
 
P.233 掲載の参考文献
1) Wysokinski WE, Gosk-Bierska I, Greene EL, et al : Clinical characteristics and long-term follow-up of patients with renal vein thrombosis. Am J Kidney Dis 51 : 224-232, 2008.
 
2) Rottenstreich A, Barzilai M, Da'as N, et al : Active malignancy in patients with renal vein thrombosis : influence upon clinical course and survival. Clin Exp Nephrol 21 : 49-54, 2017.
 
3) Wanaratwichit P, Chai-Adisaksopha C, Inmutto N, et al : Risk factors of worsening kidney function and mortality in patients with renal vein thrombosis : a retrospective study. J Nephrol 37 : 131-140, 2024.
 
4) Mahmoodi BK, ten Kate MK, Waanders F, et al : High absolute risks and predictors of venous and arterial thromboembolic events in patients with nephrotic syndrome : results from a large retrospective cohort study. Circulation 117 : 224-230, 2008.
 
5) El Zorkany K, Bridson JM, Sharma A, et al : Transplant Renal Vein Thrombosis. Exp Clin Transplant 15 : 123-129, 2017.
 
6) Cambou L, Millet C, Terrier N, et al : Management and Outcome After Early Renal Transplant Vein Thrombosis : A French Multicentre Observational Study of Real-Life Practice Over 24 Years. Transpl Int 36 : 10556, 2023.
 
7) Brandao LR, Simpson EA, Lau KK : Neonatal renal vein thrombosis. Semin Fetal Neonatal Med 16 : 323-328, 2011.
 
8) Moudgil A : Renal venous thrombosis in neonates. Curr Pediatr Rev 10 : 101-106, 2014.
 
9) Moaddab A, Shamshirsaz AA, Ruano R, et al : Prenatal Diagnosis of Renal Vein Thrombosis : A Case Report and Literature Review. Fetal Diagn Ther 39 : 228-233, 2016.
 
10) Kerlin BA, Ayoob R, Smoyer WE : Epidemiology and pathophysiology of nephrotic syndrome-associated thromboembolic disease. Clin J Am Soc Nephrol 7 : 513-520, 2012.
 
11) Mui LW, Lau JF, Lee HK : Thromboembolic complications of COVID-19. Emerg Radiol 28 : 423-429, 2021.
 
12) Platt JF, Ellis JH, Rubin JM : Intrarenal arterial Doppler sonography in the detection of renal vein thrombosis of the native kidney. AJR Am J Roentgenol 162 : 1367-1370, 1994.
 
13) Zhang LJ, Wu X, Yang GF, et al : Three-dimensional contrast-enhanced magnetic resonance venography for detection of renal vein thrombosis : comparison with multidetector CT venography. Acta Radiol 54 : 1125-1131, 2013.
 
14) Shimada Y, Nagaba Y, Nagaba H, et al : Edoxaban was Effective for Treating Renal Vein Thrombosis in a Patient with Nephrotic Syndrome. Intern Med 56 : 2307-2310, 2017.
 
15) Zhang L, Li C, Hua Z, et al : Comparative outcomes of anticoagulation alone versus anticoagulation plus endovascular intervention in adults with isolated renal vein thrombosis. J Vasc Surg Venous Lymphat Disord 11 : 816-823, 2023.
 

V 血管炎

P.241 掲載の参考文献
1) Fries JF, Hunder GG, Bloch DA, et al : The American College of Rheumatology 1990 criteria for the classification of vasculitis. Summary. Arthritis Rheum 33 : 1135-1136, 1990.
 
2) Jennette JC, Falk RJ, Andrassy K, et al : Nomenclature of systemic vasculitides. Proposal of an international consensus conference. Arthritis Rheum 37 : 187-192, 1994.
 
3) Chen M, Kallenberg CG : ANCA-associated vasculitides-advances in pathogenesis and treatment. Nat Rev Rheumatol 6 : 653-664, 2010.
 
4) Jennette JC, Falk RJ, Bacon PA, et al : 2012 revised International Chapel Hill Consensus Conference Nomenclature of Vasculitides. Arthritis Rheum 65 : 1-11, 2013.
 
5) Watts R, Lane S, Hanslik T, et al : Development and validation of a consensus methodology for the classification of the ANCA-associated vasculitides and polyarteritis nodosa for epidemiological studies. Ann Rheum Dis 66 : 222-227, 2007.
PubMed
6) Grayson PC, Ponte C, Suppiah R, et al : 2022 American College of Rheumatology/EULAR classification criteria for Takayasu arteritis. Ann Rheum Dis 81 : 1654-1660, 2022.
 
7) Ponte C, Grayson PC, Robson JC, et al : 2022 American College of Rheumatology/EULAR classification criteria for giant cell arteritis. Ann Rheum Dis 81 : 1647-1653, 2022.
 
8) Suppiah R, Robson JC, Grayson PC, et al : 2022 American College of Rheumatology/European Alliance of Associations for Rheumatology classification criteria for microscopic polyangiitis. Ann Rheum Dis 81 : 321-326, 2022.
 
9) Robson JC, Grayson PC, Ponte C, et al : 2022 American College of Rheumatology/European Alliance of Associations for Rheumatology classification criteria for granulomatosis with polyangiitis. Ann Rheum Dis 81 : 315-320, 2022.
PubMed
10) Grayson PC, Ponte C, Suppiah R, et al : 2022 American College of Rheumatology/European Alliance of Associations for Rheumatology Classification Criteria for Eosinophilic Granulomatosis with Polyangiitis. Ann Rheum Dis 81 : 309-314, 2022.
 
11) Sada KE, Kaname S, Higuchi T, et al : Validation of new ACR/EULAR 2022 classification criteria for anti-neutrophil cytoplasmic antibody-associated vasculitis. Mod Rheumatol 34 : 144-150, 2023.
 
P.248 掲載の参考文献
1) 日本循環器学会, 日本医学放射線学会, 日本眼科学会, ほか : 2015-2016年度活動血管炎症候群の珍療ガイドライン (2017年改訂版), 2018. [https://www.j-circ.or.jp/cms/wp-content/uploads/2020/02/JCS2017_isobe_h.pdf] (2024年6月閲覧)
 
2) Tombetti E, Mason JC : Takayasu arteritis : advanced understanding is leading to new horizons. Rheumatology (Oxford) 58 : 206-219, 2019.
 
3) Rutter M, Bowley J, Lanyon PC, et al : A systematic review and meta-analysis of the incidence rate of Takayasu arteritis. Rheumatology (Oxford) 60 : 4982-4990, 2021.
 
4) Tombetti E, Hysa E, Mason JC, et al : Blood Biomarkers for Monitoring and Prognosis of Large Vessel Vasculitides. Curr Rheumatol Rep 23 : 17, 2021.
 
5) 前嶋康浩 : 高安動脈炎. 日本臨牀 80 : 1216-1222, 2022.
 
6) Tamura N, Maejima Y, Tezuka D, et al : Profiles of serum cytokine levels in Takayasu arteritis patients : Potential utility as biomarkers for monitoring disease activity. J Cardiol 70 : 278-285, 2017.
 
7) Tamura N, Maejima Y, Shiheido-Watanabe Y, et al : Plasma apolipopotein C-2 elevation is associated with Takayasu arteritis. Sci Rep 11 : 18958, 2021.
 
8) 白井剛志 : 高安動脈炎のバイオマーカー. 日本臨牀 80 : 1315-1319, 2022.
 
9) Shirai T, Fujii H, Ono M, et al : An innovative method to identify autoantigens expressed on the endothelial cell surface : serological identification system for autoantigens using a retroviral vector and flow cytometry (SARF). Clin Dev Immunol 2013 : 453058, 2013.
 
10) Tezuka D, Maejima Y, Sasano T, et al : Diagnostic Role and Feasibility of 18F-FDG PET for Assessing Takayasu Arteritis : Diagnostic Efficacy of Quantifying 18F-FDG Uptake. Ann Nucl Cardiol 6 : 74-80, 2020.
 
11) Tezuka D, Haraguchi G, Ishihara T, et al : Role of FDG PET-CT in Takayasu Arteritis : Sensitive Detection of Recurrences. JACC Cardiovasc Imaging 5 : 422-429, 2012.
 
12) Nakaoka Y, Higuchi K, Arita Y, et al : Tocilizumab for the treatment of patients with refractory Takayasu arteritis. lnt Heart J 54 : 405-411, 2013.
 
13) Nakaoka Y, Isobe M, Takei S, et al : Efficacy and safety of tocilizumab in patients with refractory Takayasu arteritis : results from a randomised, double-blind, placebo-controlled, phase 3 trial in Japan (the TAKT study). Ann Rheum Dis 77 : 348-354, 2018.
PubMed
P.253 掲載の参考文献
1) 杉原毅彦 : 巨細胞動脈炎. Evidence Based Medicineを活かす膠原病・リウマチ診療 第4版 (針谷正祥編), p479-487, メジカルビュー社, 2020.
 
2) Corbera-Bellalta M, Alba-Rovira R, Muralidharan S, et al : Blocking GM-CSF receptor α with mavrilimumab reduces infiltrating cells, pro-inflammatory markers and neoangiogenesis in ex vivo cultured arteries from patients with giant cell arteritis. Ann Rheum Dis 81 : 524-536, 2022.
 
3) Sugihara T, Hasegawa H, Uchida HA, et al : Associated factors of poor treatment outcomes in patients with giant cell arteritis : clinical implication of large vessel lesions. Arthritis Res Ther 22 : 72, 2020.
 
4) Tuckwell K, Collinson N, Dimonaco S, et al : Newly diagnosed vs. relapsing giant cell arteritis : Baseline data from the GiACTA trial. Semin Arthritis Rheum 46 : 657-664, 2017.
 
5) Gribbons KB, Ponte C, Carette S, et al : Patterns of Arterial Disease in Takayasu Arteritis and Giant Cell Arteritis. Arthritis Care Res (Hoboken) 72 : 1615-1624, 2020.
 
6) Ponte C, Grayson PC, Robson JC, et al : 2022 American College of Rheumatology/EULAR classification criteria for giant cell arteritis. Ann Rheum Dis 81 : 1647-1653, 2022.
 
7) Isobe M, Amano K, Arimura Y, et al : JCS 2017 Guideline on Management of Vasculitis Syndrome-Digest Version. Circ J 84 : 299-359, 2020.
 
8) Hellmich B, Agueda A, Monti S, et al : 2018 Update of the EULAR recommendations for the management of large vessel vasculitis. Ann Rheum Dis 79 : 19-30, 2020.
 
9) Sugihara T, Yoshifuji H, Uchida HA, et al : Establishing clinical remission criteria for giant cell arteritis : Results of a Delphi exercise carried out by an expert panel of the Japan Research Committee of the Ministry of Health, Labour, and Welfare for Intractable Vasculitis. Mod Rheumatol 34 : 568-575, 2024.
 
10) Maz M, Chung SA, Abril A, et al : 2021 American College of Rheumatology/Vasculitis Foundation Guideline for the Management of Giant Cell Arteritis and Takayasu Arteritis. Arthritis Care Res (Hoboken) 73 : 1071-1087, 2021.
 
11) Stone JH, Klearman M, Collinson N : Trial of Tocilizumab in Giant-Cell Arteritis. N Engl J Med 377 : 1494-1495, 2017.
 
12) Mukhtyar C, Guillevin L, Cid MC, et al : EULAR recommendations for the management of large vessel vasculitis. Ann Rheum Dis 68 : 318-323, 2009.
 
13) Kermani TA, Sreih AG, Cuthbertson D, et al : Evaluation of damage in giant cell arteritis. Rheumatology (Oxford) 57 : 322-328, 2018.
 
14) 杉原毅彦 : 巨細胞性動脈炎. リウマチ病学テキスト 改訂第3版 (日本リウマチ財団教育研修委員会, 日本リウマチ学会生涯教育委員会編), p251-254, 南江堂, 2022.
 
P.259 掲載の参考文献
1) Jennette JC, Falk RJ, Andrassy K, et al : Nomenclature of systemic vasculitides. Proposal of an international consensus conference. Arthritis Rheum 37 : 187-192, 1994.
 
2) Jennette JC, Falk RJ, Bacon PA, et al : 2012 revised International Chapel Hill Consensus Conference Nomenclature of Vasculitides. Arthritis Rheum 65 : 1-11, 2013.
 
3) Watts RA, Lane SE, Bentham G, et al : Epidemiology of systemic vasculitis : a ten-year study in the United Kingdom. Arthritis Rheum 43 : 414-419, 2000.
 
4) Mohammad AJ, Jacobsson LT, Westman KW, et al : Incidence and survival rates in Wegener's granulomatosis, microscopic polyangiitis, Churg-Strauss syndrome and polyarteritis nodosa. Rheumatology (Oxford) 48 : 1560-1565, 2009.
 
5) Gonzalez-Gay MA, Garcia-Porrua C, Guerrero J, et al : The epidemiology of the primary systemic vasculitides in northwest Spain : implications of the Chapel Hill Consensus Conference definitions. Arthritis Rheum 49 : 388-393, 2003.
 
6) Makiyama A, Abe Y, Furusawa H, et al : Polyarteritis nodosa diagnosed in a young male after COVID-19 vaccine : A case report. Mod Rheumatol Case Rep 8 : 125-132, 2023.
 
7) Luqmani R, Awisat A : Polyarteritis nodosa and related disorders. In : Firestein & Kelley's Textbook of Rheumatology, 11th ed (ed by Firestein GS, Budd RC, Gabriel SE, et al), p1634-1648, Elsevier, Philadelphia, 2021.
 
8) 血管炎症候群の診療ガイドライン (2017年改訂版), 日本循環器学会, 2018. [https://www.j-circ.or.jp/cms/wp-content/uploads/2020/02/JCS2017_isobe_h.pdf] (2024年6月閲覧)
 
9) Abe Y, Tada K, Yamaji K, et al : Association of five-factor score with the mortality in Japanese patients with polyarteritis nodosa. Mod Rheumatol 28 : 308-312, 2018.
 
10) Rohmer J, Nguyen Y, Trefond L, et al ; French Vasculitis Study Group (FVSG) : Clinical features and long-term outcomes of patients with systemic polyarteritis nodosa diagnosed since 2005 : Data from 196 patients. J Autoimmun 139 : 103093, 2023.
 
11) Ozaki K, Miyayama S, Ushiogi Y, et al : Renal involvement of polyarteritis nodosa : CT and MR findings. Abdom Imaging 34 : 265-270, 2009.
 
12) Lightfoot RW Jr, Michel BA, Bloch DA, et al : The American College of Rheumatology 1990 criteria for the classification of polyarteritis nodosa. Arthritis Rheum 33 : 1088-1093, 1990.
PubMed
13) Forbess L, Bannykh S : Polyarteritis nodosa. Rheum Dis Clin North Am 41 : 33-46, vii, 2015.
 
14) Nakamura T, Kanazawa N, Ikeda T, et al : Cutaneous polyarteritis nodosa : revisiting its definition and diagnostic criteria. Arch Dermatol Res 301 : 117-121, 2009.
 
15) 抗リン脂質抗体症候群・好酸球性多発血管炎性肉芽腫症・結節性多発動脈炎・リウマトイド血管炎の治療の手引き 2020 (厚生労働科学研究費補助金 (難治性疾患政策研究事業) 難治性血管炎に関する調査研究 : 針谷正祥編), 診断と治療社, 2021.
 
16) Guillevin L, Lhote F, Gayraud M, et al : Prognostic factors in polyarteritis nodosa and Churg-Strauss syndrome. A prospective study in 342 patients. Medicine (Baltimore) 75 : 17-28, 1996.
PubMed
17) Chung SA, Gorelik M, Langford CA, et al : 2021 American College of Rheumatology/Vasculitis Foundation Guideline for the Management of Polyarteritis Nodosa. Arthritis Rheumatol 73 : 1384-1393, 2021.
 
18) Guillevin L, Pagnoux C, Seror R, et al : The Five-Factor Score revisited : assessment of prognoses of systemic necrotizing vasculitides based on the French Vasculitis Study Group (FVSG) cohort. Medicine (Baltimore) 90 : 19-27, 2011.
 
19) Zhou Q, Yang D, Ombrello AK, et al : Early-onset stroke and vasculopathy associated with mutations in ADA2. N Engl J Med 370 : 911-920, 2014.
 
P.267 掲載の参考文献
1) 中村好一 : 川崎病診断の手引きの変遷. 川崎病学 [改訂第2版] (日本川崎病学会編), p8-11, 診断と治療社, 2021.
 
2) 日本川崎病学会 : 川崎病診断の手引き 改訂第6版. [https://jskd.jp/wp-content/uploads/2022/10/tebiki201906.pdf] (2024年7月閲覧)
 
3) Ikeda K, Yamaguchi K, Tanaka T, et al : Unique activation status of peripheral blood mononuclear cells at acute phase of Kawasaki disease. Clin Exp Immunol 160 : 246-255, 2010.
 
4) Inada Y, Sonoda M, Mizuno Y, et al : CD14 down-modulation as a real-time biomarker in Kawasaki disease. Clin Transl Immunology 13 : e1482, 2023.
 
5) 日本小児循環器学会学術委員会 : 川崎病急性期治療のガイドライン (2020年改訂版). 日本小児循環器学会雑誌 36 : S1.1-S1.29, 2020.
 
6) Kobayashi T, Inoue Y, Takeuchi K, et al : Prediction of intravenous immunoglobulin unresponsiveness in patients with Kawasaki disease. Circulation 113 : 2606-2612, 2006.
 
7) Egami K, Muta H, Ishii M, et al : Prediction of resistance to intravenous immunoglobulin treatment in patients with Kawasaki disease. J Pediatr 149 : 237-240, 2006.
 
8) Sano T, Kurotobi S, Matsuzaki K, et al : Prediction of non-responsiveness to standard high-dose gamma-globulin therapy in patients with acute Kawasaki disease before starting initial treatment. Eur J Pediatr 166 : 131-137, 2007.
 
9) Oda T, Nagata H, Nakashima Y, et al : Clinical Utility of Highly Purified 10% Liquid Intravenous Immunoglobulin in Kawasaki Disease. J Pediatr 214 : 227-230, 2019.
 
10) Kobayashi T, Saji T, Otani T, et al : Efficacy of immunoglobulin plus prednisolone for prevention of coronary artery abnormalities in severe Kawasaki disease (RAISE study) : a randomised, open-label, blinded-endpoints trial. Lancet 379 : 1613-1620, 2012.
 
11) Ogata S, Ogihara Y, Honda T, et al : Corticosteroid pulse combination therapy for refractory Kawasaki disease : a randomized trial. Pediatrics 129 : e17-23, 2012.
 
12) Hamada H, Suzuki H, Onouchi Y, et al : Efficacy of primary treatment with immunoglobulin plus ciclosporin for prevention of coronary artery abnormalities in patients with Kawasaki disease predicted to be at increased risk of non-response to intravenous immunoglobulin (KAICA) : a randomised controlled, open-label, blinded-endpoints, phase 3 trial. Lancet 393 : 1128-1137, 2019.
PubMed
13) Miura M, Kobayashi T, Igarashi T, et al : Real-world Safety and Effectiveness of Infliximab in Pediatric Patients With Acute Kawasaki Disease : A Postmarketing Surveillance in Japan (SAKURA Study). Pediatr Infect Dis J 39 : 41-47, 2020.
 
14) Kanai T, Ishiwata T, Kobayashi T, et al : Ulinastatin, a urinary trypsin inhibitor, for the initial treatment of patients with Kawasaki disease : a retrospective study. Circulation 124 : 2822-2828, 2011.
 
15) Sonoda K, Mori M, Hokosaki T, et al : Infliximab plus plasma exchange rescue therapy in Kawasaki disease. J Pediatr 164 : 1128-1132.e1, 2014.
 
P.273 掲載の参考文献
1) Jennette JC, Falk RJ, Andrassy K, et al : Nomenclature of systemic vasculitides. Proposal of an international consensus conference. Arthritis Rheum 37 : 187-192, 1994.
 
2) Jennette JC, Falk RJ, Bacon PA, et al : 2012 revised International Chapel Hill Consensus Conference Nomenclature of Vasculitides. Arthritis Rheum 65 : 1-11, 2013.
 
3) Davies DJ, Moran JE, Niall JF, et al : Segmental necrotising glomerulonephritis with antineutrophil antibody : possible arbovirus aetiology? Br Med J (Clin Res Ed) 285 : 606, 1982.
 
4) Jennette JC, Falk RJ : Small-vessel vasculitis. N Engl J Med 337 : 1512-1523, 1997.
PubMed
5) Fujimoto S, Watts RA, Kobayashi S, et al : Comparison of the epidemiology of anti-neutrophil cytoplasmic antibody-associated vasculitis between Japan and the U.K. Rheumatology (Oxford) 50 : 1916-1920, 2011.
 
6) Sada KE, Yamamura M, Harigai M, et al : Classification and characteristics of Japanese patients with antineutrophil cytoplasmic antibody-associated vasculitis in a nationwide, prospective, inception cohort study. Arthritis Res Ther 16 : R101, 2014.
 
7) Lyons PA, Rayner TF, Trivedi S, et al : Genetically distinct subsets within ANCA-associated vasculitis. N Engl J Med 367 : 214-223, 2012.
 
8) Trivioli G, Marquez A, Martorana D, et al : Genetics of ANCA-associated vasculitis : role in pathogenesis, classification and management. Nat Rev Rheumatol 18 : 559-574, 2022.
 
9) Nakazawa D, Masuda S, Tomaru U, et al : Pathogenesis and therapeutic interventions for ANCA-associated vasculitis. Nat Rev Rheumatol 15 : 91-101, 2019.
PubMed
10) Furuta S, Chaudhry AN, Hamano Y, et al : Comparison of phenotype and outcome in microscopic polyangiitis between Europe and Japan. J Rheumatol 41 : 325-333, 2014.
 
11) Suppiah R, Robson JC, Grayson PC, et al : 2022 American College of Rheumatology/European Alliance of Associations for Rheumatology classification criteria for microscopic polyangiitis. Ann Rheum Dis 81 : 321-326, 2022.
 
12) Hellmich B, Sanchez-Alamo B, Schirmer JH, et al : EULAR recommendations for the management of ANCA-associated vasculitis : 2022 update. Ann Rheum Dis 83 : 30-47, 2024.
 
13) Furuta S, Nakagomi D, Kobayashi Y, et al : Effect of Reduced-Dose vs High-Dose Glucocorticoids Added to Rituximab on Remission Induction in ANCA-Associated Vasculitis : A Randomized Clinical Trial. JAMA 325 : 2178-2187, 2021.
PubMed
14) Walsh M, Merkel PA, Peh CA, et al : Plasma Exchange and Glucocorticoids in Severe ANCA-Associated Vasculitis. N Engl J Med 382 : 622-631, 2020.
 
15) Jayne DRW, Merkel PA, Schall TJ, et al : Avacopan for the Treatment of ANCA-Associated Vasculitis. N Engl J Med 384 : 599-609, 2021.
PubMed
16) Yamaguchi S, Yamazaki M, Kido T, et al : A case of vanishing bile duct syndrome during treatment of microscopic polyangiitis with avacopan. Rheumatology (Oxford) 63 : e120-e122, 2024.
 
17) Guillevin L, Pagnoux C, Karras A, et al : Rituximab versus azathioprine for maintenance in ANCA-associated vasculitis. N Engl J Med 371 : 1771-1780, 2014.
PubMed
18) Charles P, Terrier B, Perrodeau E, et al : Comparison of individually tailored versus fixed-schedule rituximab regimen to maintain ANCA-associated vasculitis remission : results of a multicentre, randomised controlled, phase III trial (MAINRITSAN2). Ann Rheum Dis 77 : 1143-1149, 2018.
 
19) Delestre F, Charles P, Karras A, et al : Rituximab as maintenance therapy for ANCA-associated vasculitides : pooled analysis and long-term outcome of 277 patients included in the MAINRITSAN trials. Ann Rheum Dis 83 : 233-241, 2024.
 
20) Terrier B, Pagnoux C, Perrodeau E, et al : Long-term efficacy of remission-maintenance regimens for ANCA-associated vasculitides. Ann Rheum Dis 77 : 1150-1156, 2018.
 
21) Zonozi R, Cortazar FB, Jeyabalan A, et al : Maintenance of remission of ANCA vasculitis by rituximab based on B cell repopulation versus serological flare : a randomised trial. Ann Rheum Dis 83 : 351-359, 2024.
 
22) Smith RM, Jones RB, Specks U, et al : Rituximab as therapy to induce remission after relapse in ANCA-associated vasculitis. Ann Rheum Dis 79 : 1243-1249, 2020.
 
23) Smith RM, Jones RB, Specks U, et al : Rituximab versus azathioprine for maintenance of remission for patients with ANCA-associated vasculitis and relapsing disease : an international randomised controlled trial. Ann Rheum Dis 82 : 937-944, 2023.
 
P.279 掲載の参考文献
1) Wegener F : Uber eine eigenartige rhinogene Guranulomatose mit besonderer beteiligung des Arteriensystems und der Nieren. Beitr Pathol Anat 102 : 36-68, 1939.
 
2) Jennette JC, Falk RJ, Bacon PA, et al : 2012 revised International Chapel Hill Consensus Conference Nomenclature of Vasculitides. Arthritis Rheum 65 : 1-11, 2013.
 
3) Chung SA, Langford CA, Maz M, et al : 2021 American College of Rheumatology/Vasculitis Foundation Guideline for the Management of Antineutrophil Cytoplasmic Antibody-Associated Vasculitis. Arthritis Care Res (Hoboken) 73 : 1088-1105, 2021.
 
4) Robson JC, Grayson PC, Ponte C, et al : 2022 American College of Rheumatology/European Alliance of Associations for Rheumatology Classification Criteria for Granulomatosis With Polyangiitis. Arthritis Rheumatol 74 : 393-399, 2022.
 
5) ANCA関連血管炎診療ガイドライン 2023 (針谷正祥, 成田一衛, 須田隆文編), 診断と治療社, 2023.
 
6) 難病情報センター : 特定医療費 (指定難病) 受給者証所持者数 [https://www.nanbyou.or.jp/entry/5354] (2024年7月閲覧).
 
7) Sada KE, Yamamura M, Harigai M, et al : Classification and characteristics of Japanese patients with antineutrophil cytoplasmic antibody-associated vasculitis in a nationwide, prospective, inception cohort study. Arthritis Res Ther 16 : R101, 2014.
 
8) Esnault VL, Audrain MA, Sesboue R : Alpha-1-antitrypsin phenotyping in ANCA-associated diseases : one of several arguments for protease/antiprotease imbalance in systemic vasculitis. Exp Clin Immunogenet 14 : 206-213, 1997.
 
9) Heckmann M, Holle JU, Arning L, et al : The Wegener's granulomatosis quantitative trait locus on chromosome 6p21.3 as characterised by tagSNP genotyping. Ann Rheum Dis 67 : 972-979, 2008.
 
10) van der Woude FJ, Rasmussen N, Lobatto S, et al : Autoantibodies against neutrophils and monocytes : tool for diagnosis and marker of disease activity in Wegener's granulomatosis. Lancet 1 : 425-429, 1985.
 
11) Jennette JC, Falk RJ, Andrassy K, et al : Nomenclature of systemic vasculitides. Proposal of an international consensus conference. Arthritis Rheum 37 : 187-192, 1994.
 
12) 山村昌弘 : 多発血管炎性肉芽腫症 (旧 Wegener肉芽腫症). リウマチ科 50 : 441-449, 2013.
 
13) 吉田雅治 : Wegener肉芽腫症. 日本臨牀 64 (増刊 : 分子腎臓病学) : 460-466, 2006.
 
14) Hellmich B, Sanchez-Alamo B, Schirmer JH, et al : EULAR recommendations for the management of ANCA-associated vasculitis : 2022 update. Ann Rheum Dis 83 : 30-47, 2024.
 
15) Sada KE, Yamamura M, Harigai M, et al : Different responses to treatment across classified diseases and severities in Japanese patients with microscopic polyangiitis and granulomatosis with polyangiitis : a nationwide prospective inception cohort study. Arthritis Res Ther 17 : 305, 2015.
 
P.285 掲載の参考文献
1) Jennette JC, Falk RJ, Bacon PA, et al : 2012 revised International Chapel Hill Consensus Conference Nomenclature of Vasculitides. Arthritis Rheum 65 : 1-11, 2013.
 
2) Sada KE, Amano K, Uehara R, et al : A nationwide survey on the epidemiology and clinical features of eosinophilic granulomatosis with polyangiitis (Churg-Strauss) in Japan. Mod Rheumatol 24 : 640-644, 2014.
 
3) 厚生労働省令和4年度衛生行政報告例
 
4) Lanham JG, Elkon KB, Pusey CD, et al : Systemic vasculitis with asthma and eosinophilia : a clinical approach to the Churg-Strauss syndrome. Medicine (Baltimore) 63 : 65-81, 1984.
 
5) ANCA関連血管炎診療ガイドライン 2023 (厚生労働科学研究費補助金難治性疾患政策研究事業 ; 針谷正祥, 成田一衛, 須田隆文編), p144-149, 診断と治療社, 2023.
 
6) Grayson PC, Ponte C, Suppiah R, et al : 2022 American College of Rheumatology/European Alliance of Associations for Rheumatology Classification Criteria for Eosinophilic Granulomatosis with Polyangiitis. Ann Rheum Dis 81 : 309-314, 2022.
 
7) Sada KE, Kaname S, Higuchi T, et al : Validation of new ACR/EULAR 2022 classification criteria for anti-neutrophil cytoplasmic antibody-associated vasculitis. Mod Rheumatol 34 : 144-150, 2023.
 
8) Guillevin L, Pagnoux C, Seror R, et al : The Five-Factor Score revisited : assessment of prognoses of systemic necrotizing vasculitides based on the French Vasculitis Study Group (FVSG) cohort. Medicine (Baltimore) 90 : 19-27, 2011.
 
9) 抗リン脂質抗体症候群・好酸球性多発血管炎性肉芽腫症・結節性多発動脈炎・リウマトイド血管炎の治療の手引き 2020 (厚生労働科学研究費補助金 (難治性疾患政策研究事業) 難治性血管炎に関する調査研究 : 針谷正祥編), p39-50, 診断と治療社, 2021.
 
10) Wechsler ME, Akuthota P, Jayne D, et al : Mepolizumab or Placebo for Eosinophilic Granulomatosis with Polyangiitis. N Engl J Med 376 : 1921-1932, 2017.
 
11) Chung SA, Langford CA, Maz M, et al : 2021 American College of Rheumatology/Vasculitis Foundation Guideline for the Management of Antineutrophil Cytoplasmic Antibody-Associated Vasculitis. Arthritis Care Res (Hoboken) 73 : 1088-1105, 2021.
 
12) Hellmich B, Sanchez-Alamo B, Schirmer JH, et al : EULAR recommendations for the management of ANCA-associated vasculitis : 2022 update. Ann Rheum Dis 83 : 30-47, 2024.
 
13) Ishii T, Kunishige H, Kobayashi T, et al : Real-world safety and effectiveness of mepolizumab for patients with eosinophilic granulomatosis with polyangiitis (EGPA) in Japan : 48-week interim analysis of the MARS study. Mod Rheumatol, 2023. (DOI : 10.1093/mr/road109)
 
14) Wechsler ME, Nair P, Terrier B, et al : Benralizumab versus Mepolizumab for Eosinophilic Granulomatosis with Polyangiitis. N Engl J Med 390 : 911-921, 2024.
 
P.290 掲載の参考文献
1) Jennette JC, Falk RJ, Bacon PA, et al : 2012 revised International Chapel Hill Consensus Conference Nomenclature of Vasculitides. Arthritis Rheum 65 : 1-11, 2013.
 
2) Pedchenko V, Bondar O, Fogo AB, et al : Molecular architecture of the Goodpasture autoantigen in anti-GBM nephritis. N Engl J Med 363 : 343-354, 2010.
 
3) Netzer KO, Leinonen A, Boutaud A, et al : The goodpasture autoantigen. Mapping the major conformational epitope (s) of alpha3 (IV) collagen to residues 17-31 and 127-141 of the NC1 domain. J Biol Chem 274 : 11267-11274, 1999.
 
4) Ooi JD, Petersen J, Tan YH, et al : Dominant protection from HLA-linked autoimmunity by antigen-specific regulatory T cells. Nature 545 : 243-247, 2017.
 
5) 磯部光章, ほか : 血管炎症候群の診療ガイドライン (2017年改訂版), p71-75, 日本循環器学会, 2018.
 
6) Koyama A, Yamagata K, Makino H, et al : A nationwide survey of rapidly progressive glomerulonephritis in Japan : etiology, prognosis and treatment diversity. Clin Exp Nephrol 13 : 633-650, 2009.
 
7) Levy JB, Hammad T, Coulthart A, et al : Clinical features and outcome of patients with both ANCA and anti-GBM antibodies. Kidney Int 66 : 1535-1540, 2004.
 
8) Olson SW, Arbogast CB, Baker TP, et al : Asymptomatic autoantibodies associate with future anti-glomerular basement membrane disease. J Am Soc Nephrol 22 : 1946-1952, 2011.
 
9) Floyd L, Bate S, Hadi Kafagi A, et al : Risk Stratification to Predict Renal Survival in Anti-Glomerular Basement Membrane Disease. J Am Soc Nephrol 34 : 505-514, 2023.
 
10) 松尾清一, 山縣邦弘, 槇野博史, ほか : 急速進行性腎炎症候群の診療指針 第2版. 日本腎臓学会誌 53 : 509-555, 2011.
 
11) Alchi B, Griffiths M, Sivalingam M, et al : Predictors of renal and patient outcomes in anti-GBM disease : clinicopathologic analysis of a two-centre cohort. Nephrol Dial Transplant 30 : 814-821, 2015.
 
12) Ohkubo A, Okado T, Kurashima N, et al : Removal Characteristics of Immunoglobulin G Subclasses by Conventional Plasma Exchange and Selective Plasma Exchange. Ther Apher Dial 19 : 361-366, 2015.
 
13) Levy JB, Lachmann RH, Pusey CD : Recurrent Goodpasture's disease. Am J Kidney Dis 27 : 573-578, 1996.
 
14) Biesenbach P, Kain R, Derfler K, et al : Long-term outcome of anti-glomerular basement membrane antibody disease treated with immunoadsorption. PLoS One 9 : e103568, 2014.
 
15) Uhlin F, Szpirt W, Kronbichler A, et al : Endopeptidase Cleavage of Anti-Glomerular Basement Membrane Antibodies in vivo in Severe Kidney Disease : An Open-Label Phase 2a Study. J Am Soc Nephrol 33 : 829-838, 2022.
 
P.297 掲載の参考文献
1) Ramos-Casals M, Stone JH, Cid MC, et al : The cryoglobulinaemias. Lancet 379 : 348-360, 2012.
PubMed
2) Kolopp-Sarda MN, Nombel A, Miossec P : Cryoglobulins Today : Detection and Immunologic Characteristics of 1,675 Positive Samples From 13,439 Patients Obtained Over Six Years. Arthritis Rheumatol 71 : 1904-1912, 2019.
 
3) Cacoub P, Comarmond C, Vieira M, et al : HCV-related lymphoproliferative disorders in the directacting antiviral era : From mixed cryoglobulinaemia to B-cell lymphoma. J Hepatol 76 : 174-185, 2022.
 
4) Nocturne G, Pontarini E, Bombardieri M, et al : Lymphomas complicating primary Sjogren's syndrome : from autoimmunity to lymphoma. Rheumatology (Oxford) 60 : 3513-3521, 2021.
 
5) Kondili LA, Monti M, Quaranta MG, et al : A prospective study of direct-acting antiviral effectiveness and relapse risk in HCV cryoglobulinemic vasculitis by the Italian PITER cohort. Hepatology 76 : 220-232, 2022.
 
6) Brito-Zeron P, Flores-Chavez A, Horvath IF, et al : Mortality risk factors in primary Sjogren syndrome : a real-world, retrospective, cohort study. EClinicalMedicine 61 : 102062, 2023.
 
7) Argyropoulou OD, Pezoulas V, Chatzis L, et al : Cryoglobulinemic vasculitis in primary Sjogren's Syndrome : Clinical presentation, association with lymphoma and comparison with Hepatitis C-related disease. Semin Arthritis Rheum 50 : 846-853, 2020.
 
8) Kallemuchikkal U, Gorevic PD : Evaluation of cryoglobulins. Arch Pathol Lab Med 123 : 119-125, 1999.
PubMed
9) Scarpato S, Atzeni F, Sarzi-Puttini P, et al : Pain management in cryoglobulinaemic syndrome. Best Pract Res Clin Rheumatol 29 : 77-89, 2015.
 
10) Hsu JL, Liao MF, Hsu HC, et al : A prospective, observational study of patients with uncommon distal symmetric painful small-fiber neuropathy. PLoS One 12 : e0183948, 2017.
 
11) Ramos-Casals M, Robles A, Brito-Zeron P, et al : Life-threatening cryoglobulinemia : clinical and immunological characterization of 29 cases. Semin Arthritis Rheum 36 : 189-196, 2006.
 
12) Habas E Sr, Farfar KL, Errayes N, et al : Hepatitis Virus C-associated Nephropathy : A Review and Update. Cureus 14 : e27322, 2022.
 
13) Dammacco F, Lauletta G, Vacca A : The wide spectrum of cryoglobulinemic vasculitis and an overview of therapeutic advancements. Clin Exp Med 23 : 255-272, 2023.
 
14) Gragnani L, Lorini S, Marri S, et al : Hematological and Genetic Markers in the Rational Approach to Patients With HCV Sustained Virological Response With or Without Persisting Cryoglobulinemic Vasculitis. Hepatology 74 : 1164-1173, 2021.
 
15) Miao J, Krisanapan P, Tangpanithandee S, et al : Efficacy of Therapeutic Apheresis for Cryoglobulinemic Vasculitis Patients with Renal Involvement : A Systematic Review. Blood Purif 53 : 1-9, 2024.
 
P.302 掲載の参考文献
1) 難病情報センター : 紫斑病性腎炎 (指定難病224). [https://www.nanbyou.or.jp/entry/4658] (2024年6月閲覧)
 
2) Piram M, Mahr A : Epidemiology of immunoglobulin A vasculitis (Henoch-Schonlein) : current state of knowledge. Curr Opin Rheumatol 25 : 171-178, 2013.
 
3) Suzuki H, Yasutake J, Makita Y, et al : IgA nephropathy and IgA vasculitis with nephritis have a shared feature involving galactose-deficient IgA1-oriented pathogenesis. Kidney Int 93 : 700-705, 2018.
 
4) Kiryluk K, Moldoveanu Z, Sanders JT, et al : Aberrant glycosylation of IgA1 is inherited in both pediatric IgA nephropathy and Henoch-Schonlein purpura nephritis. Kidney Int 80 : 79-87, 2011.
 
5) 日本循環器学会 : 血管炎症候群の診療ガイドライン (2017年改訂版), 2018. [https://www.j-circ.or.jp/cms/wp-content/uploads/2020/02/JCS2017_isobe_h.pdf] (2024年6月閲覧)
 
6) Ozen S, Pistorio A, Iusan SM, et al : EULAR/PRINTO/PRES criteria for Henoch-Schonlein purpura, childhood polyarteritis nodosa, childhood Wegener granulomatosis and childhood Takayasu arteritis : Ankara 2008. Part II : Final classification criteria. Ann Rheum Dis 69 : 798-806, 2010.
PubMed
7) Hocevar A, Rotar Z, Jurcic V, et al : IgA vasculitis in adults : the performance of the EULAR/PRINTO/PRES classification criteria in adults. Arthritis Res Ther 18 : 58, 2016.
 
8) 日本皮膚科学血管炎・血管障害診療ガイドライン改訂版作成委員会 : 血管炎・血管障害診療ガイドライン 2016年改訂版. 日本皮膚科学会雑誌 127 : 299-415, 2017.
 
9) Rovin BH, Adler SG, Barratt J, et al : Executive summary of the KDIGO 2021 Guideline for the Management of Glomerular Diseases. Kidney Int 100 : 753-779, 2021.
PubMed
10) Komatsu H, Fujimoto S, Maruyama S, et al : Distinct characteristics and outcomes in elderly-onset IgA vasculitis (Henoch-Schonlein purpura) with nephritis : Nationwide cohort study of data from the Japan Renal Biopsy Registry (J-RBR). PLoS ONE 13 : e0196955, 2018.
 
P.307 掲載の参考文献
1) Emmi G, Bettiol A, Hatemi G, et al : Behcet's syndrome. Lancet 403 : 1093-1108, 2024.
 
2) Bettiol A, Alibaz-Oner F, Direskeneli H, et al : Vascular Behcet syndrome : from pathogenesis to treatment. Nat Rev Rheumatol 19 : 111-126, 2023.
 
3) ベーチェット病診療ガイドライン 2020 (日本ベーチェット病学会監, 水木信久, 竹内正樹編), 診断と治療社, 2020.
 
4) Takeno M, Ideguchi H, Suda A, et al : Vascular involvement of Behcet's disease. In : Behcet's Disease : From Genetics to Therapies (ed by Ishigatsubo Y), p79-100, Springer, Tokyo, 2015.
 
5) Saadoun D, Wechsler B, Desseaux K, et al : Mortality in Behcet's disease. Arthritis Rheum 62 : 2806-2812, 2010.
 
6) 岳野光洋 : 血管病変. 日本臨牀 79 : 884-889, 2021.
 
7) Soejima Y, Kirino Y, Takeno M, et al : Changes in the proportion of clinical clusters contribute to the phenotypic evolution of Behcet's disease in Japan. Arthritis Res Ther 23 : 49, 2021.
 
8) 石ヶ坪良明, 岳野光洋, 出口治子, ほか : 血管ベーチェット病の臨床像 : ベーチェット病研究班内調査～全国疫学調査と自験例との比較. 平成23年度厚生労働科学研究費補助金 (難治性疾患克服研究事業) 総括・分担研究報告書, p76-82, 2012.
 
9) Ideguchi H, Suda A, Takeno M, et al : Characteristics of vascular involvement in Behcet's disease in Japan : a retrospective cohort study. Clin Exp Rheumatol 29 : S47-S53, 2011.
 
10) Seyahi E, Caglar E, Ugurlu S, et al : An outcome survey of 43 patients with Budd-Chiari syndrome due to Behcet's syndrome followed up at a single, dedicated center. Semin Arthritis Rheum 44 : 602-609, 2015.
 
11) Tascilar K, Melikoglu M, Ugurlu S, et al : Vascular involvement in Behcet's syndrome : a retrospective analysis of associations and the time course. Rheumatology (Oxford) 53 : 2018-2022, 2014.
 
12) Geri G, Wechsler B, Thi Huong DL, et al : Spectrum of cardiac lesions in Behcet disease : a series of 52 patients and review of the literature. Medicine (Baltimore) 91 : 25-34, 2012.
 
13) Mehdipoor G, Davatchi F, Ghoreishian H, et al : Imaging manifestations of Behcet's disease : Key considerations and major features. Eur J Radiol 98 : 214-225, 2018.
 
14) Seyahi E, Yazici H : Behcet's syndrome : pulmonary vascular disease. Curr Opin Rheumatol 27 : 18-23, 2015.
 
15) Becatti M, Emmi G, Silvestri E, et al : Neutrophil Activation Promotes Fibrinogen Oxidation and Thrombus Formation in Behcet Disease. Circulation 133 : 302-311, 2016.
 
16) Le Joncour A, Martos R, Loyau S, et al : Critical role of neutrophil extracellular traps (NETs) in patients with Behcet's disease. Ann Rheum Dis 78 : 1274-1282, 2019.
 
17) Emmi G, Bagni G, Lastraioli E, et al : A unique circulating miRNA profile highlights thromboinflammation in Behcet's syndrome. Ann Rheum Dis 81 : 386-397, 2022.
 
18) Erkan D, Yazici Y, Sanders A, et al : Is Hughes-Stovin syndrome Behcet's disease? Clin Exp Rheumatol 22 (4 Suppl 34) : S64-68, 2004.
 
19) Alibaz-Oner F, Direskeneli H : Update on the Diagnosis of Behcet's Disease. Diagnostics (Basel) 13 : 41, 2022.
 
20) Ambrose N, Pierce IT, Gatehouse PD, et al : Magnetic resonance imaging of vein wall thickness in patients with Behcet's syndrome. Clin Exp Rheumatol 32 (4 Suppl 84) : S99-102, 2014.
 
21) Alibaz-Oner F, Ergelen R, Mutis A, et al : Venous vessel wall thickness in lower extremity is increased in male patients with Behcet's disease. Clin Rheumatol 38 : 1447-1451, 2019.
 
22) Hatemi G, Christensen R, Bang D, et al : 2018 update of the EULAR recommendations for the management of Behcet's syndrome. Ann Rheum Dis 77 : 808-818, 2018.
 
23) Kone-Paut I, Barete S, Bodaghi B, et al : French recommendations for the management of Behcet's disease. Orphanet J Rare Dis 16 (Suppl 1) : 352, 2021.
 
24) Murphy R, Moots RJ, Brogan PA, et al : Paul Brogan British Association of Dermatologists and British Society for Rheumatology draft guidelines for the management of people with Behcets 2023. [https://www.rheumatology.org.uk/news/details/Open-for-consultation-Beh-ets-guideline]
 
25) Hidekawa C, Minegishi K, Kobayashi K, et al : Successful treatment of extensive venous thrombosis with combination of immunosuppressants and a direct Xa inhibitor in Behcet's disease. Mod Rheumatol Case Rep 2 : 204-208, 2018.
 
P.312 掲載の参考文献
1) Cogan DG : Syndrome of nonsyphilitic interstitial keratitis and vestibuloauditory symptoms. Arch Ophthalmol 33 : 144-149, 1945.
 
2) Tayer-Shifman OE, Ilan O, Tovi H, et al : Cogan's syndrome-clinical guidelines and novel therapeutic approaches. Clin Rev Allergy Immunol 47 : 65-72, 2014.
 
3) Kessel A, Vadasz Z, Toubi E : Cogan syndrome-pathogenesis, clinical variants and treatment approaches. Autoimmun Rev 13 : 351-354, 2014.
 
4) Lunardi C, Bason C, Leandri M, et al : Autoantibodies to inner ear and endothelial antigens in Cogan's syndrome. Lancet 360 : 915-921, 2002.
 
5) Fisher ER, Hellstrom HR : Cogan's syndrome and systemic vascular disease. Analysis of pathologic features with reference to its relationship to thromboangiitis obliterans (Buerger). Arch Pathol 72 : 572-592, 1961.
 
6) Gluth MB, Baratz KH, Matteson EL, et al : Cogan syndrome : a retrospective review of 60 patients throughout a half century. Mayo Clin Proc 81 : 483-488, 2006.
 
7) Cundiff J, Kansal S, Kumar A, et al : Cogan's syndrome : a cause of progressive hearing deafness. Am J Otolaryngol 27 : 68-70, 2006.
 
8) Haynes BF, Kaiser-Kupfer MI, Mason P, et al : Cogan syndrome : studies in thirteen patients, long-term follow-up, and a review of the literature. Medicine (Baltimore) 59 : 426-441, 1980.
 
9) Higashida-Konishi M, Akiyama M, Tabata H, et al : Atypical Cogan's Syndrome with Large-vessel Vasculitis Successfully Treated with Tocilizumab. Intern Med 62 : 3413-3417, 2023.
 
10) Orsoni JG, Lagana B, Rubino P, et al : Rituximab ameliorated severe hearing loss in Cogan's syndrome : a case report. Orphanet J Rare Dis 5 : 18, 2010.
 
11) St Clair EW, McCallum RM : Cogan's syndrome. Curr Opin Rheumatol 11 : 47-52, 1999.
 
12) Allen NB, Cox CC, Cobo M, et al : Use of immunosuppressive agents in the treatment of severe ocular and vascular manifestations of Cogan's syndrome. Am J Med 88 : 296-301, 1990.
 
13) Shibuya M, Fujio K, Morita K, et al : Successful treatment with tocilizumab in a case of Cogan's syndrome complicated with aortitis. Mod Rheumatol 23 : 577-581, 2013.
 
P.318 掲載の参考文献
1) Atisha-Fregoso Y, Hinojosa-Azaola A, Alcocer-Varela J : Localized, single-organ vasculitis : clinical presentation and management. Clin Rheumatol 32 : 1-6, 2013.
 
2) Hernandez-Rodriguez J, Hoffman GS : Updating single-organ vasculitis. Curr Opin Rheumatol 24 : 38-45, 2012.
 
3) Hernandez-Rodriguez J, Molloy ES, Hoffman GS : Single-organ vasculitis. Curr Opin Rheumatol 20 : 40-46, 2008.
 
4) Jennette JC, Falk RJ, Bacon PA, et al : 2012 revised International Chapel Hill Consensus Conference Nomenclature of Vasculitides. Arthritis Rheum 65 : 1-11, 2013.
 
5) Martins-Martinho J, Dourado E, Khmelinskii N, et al : Localized Forms of Vasculitis. Curr Rheumatol Rep 23 : 49, 2021.
 
6) Navon Elkan P, Pierce SB, Segel R, et al : Mutant adenosine deaminase 2 in a polyarteritis nodosa vasculopathy. N Engl J Med 370 : 921-931, 2014.
 
7) Gonzalez Santiago TM, Zavialov A, Saarela J, et al : Dermatologic Features of ADA2 Deficiency in Cutaneous Polyarteritis Nodosa. JAMA Dermatol 151 : 1230-1234, 2015.
 
8) Byram K, Hajj-Ali RA, Calabrese L : CNS Vasculitis : an Approach to Differential Diagnosis and Management. Curr Rheumatol Rep 20 : 37, 2018.
 
P.322 掲載の参考文献
1) Jennette JC, Falk RJ, Bacon PA, et al : 2012 revised International Chapel Hill Consensus Conference Nomenclature of Vasculitides. Arthritis Rheum 65 : 1-11, 2013.
 
2) Ramos-Casals M, Nardi N, Lagrutta M, et al : Vasculitis in systemic lupus erythematosus : prevalence and clinical characteristics in 670 patients. Medicine (Baltimore) 85 : 95-104, 2006.
 
3) Gronhagen CM, Gunnarsson I, Svenungsson E, et al : Cutaneous manifestations and serological findings in 260 patients with systemic lupus erythematosus. Lupus 19 : 1187-1194, 2010.
 
4) Jasmin R, Sockalingam S, Ramanaidu LP, et al : Clinical and electrophysiological characteristics of symmetric polyneuropathy in a cohort of systemic lupus erythematosus patients. Lupus 24 : 248-255, 2015.
 
5) Florica B, Aghdassi E, Su J, et al : Peripheral neuropathy in patients with systemic lupus erythematosus. Semin Arthritis Rheum 41 : 203-211, 2011.
 
6) Schwartz N, Stock AD, Putterman C : Neuropsychiatric lupus : new mechanistic insights and future treatment directions. Nat Rev Rheumatol 15 : 137-152, 2019.
 
7) Burgos PI, Vila LM, Reveille JD, et al : Peripheral vascular damage in systemic lupus erythematosus : data from LUMINA, a large multi-ethnic U.S. cohort (LXIX). Lupus 18 : 1303-1308, 2009.
 
8) Yuan S, Ye Y, Chen D, et al : Lupus mesenteric vasculitis : clinical features and associated factors for the recurrence and prognosis of disease. Semin Arthritis Rheum 43 : 759-766, 2014.
 
9) Barber C, Herzenberg A, Aghdassi E, et al : Evaluation of clinical outcomes and renal vascular pathology among patients with lupus. Clin J Am Soc Nephrol 7 : 757-764, 2012.
 
10) Banfi G, Bertani T, Boeri V, et al : Renal vascular lesions as a marker of poor prognosis in patients with lupus nephritis. Gruppo Italiano per lo Studio della Nefrite Lupica (GISNEL). Am J Kidney Dis 18 : 240-248, 1991.
 
11) Nasser M, Cottin V : Alveolar Hemorrhage in Vasculitis (Primary and Secondary). Semin Respir Crit Care Med 39 : 482-493, 2018.
 
12) Conigliaro P, Cesareo M, Chimenti MS, et al : Take a look at the eyes in Systemic Lupus Erythematosus : A novel point of view. Autoimmun Rev 18 : 247-254, 2019.
 
13) 北郡宏次, 三森経世 : SLEの血管炎. 日本臨牀 75 (増刊 : 動脈・静脈の疾患 (下)) : 1012-1016, 2017.
 
14) 血管炎症候群の診療ガイドライン (2017年改訂版), 日本循環器学会, 2018.
 
P.327 掲載の参考文献
1) Turesson C, Jacobsson L, Bergstrom U, et al : Extra-articular rheumatoid arthritis : prevalence and mortality. Rheumatology (Oxford) 38 : 668-674, 1999.
 
2) Makol A, Crowson CS, Wetter DA, et al : Vasculitis associated with rheumatoid arthritis : a case-control study. Rheumatology (Oxford) 53 : 890-899, 2014.
 
3) Ntatsaki E, Mooney J, Scott DG, et al : Systemic rheumatoid vasculitis in the era of modern immunosuppressive therapy. Rheumatology (Oxford) 53 : 145-152, 2014.
 
4) 難病情報センターホームページ (2024年7月現在)
 
5) Bywaters EG, Scott JT : the natural history of vascular lesions in rheumatoid arthritis. J Chronic Dis 16 : 905-914, 1963.
 
6) Scott DG, Bacon PA : Intravenous cyclophosphamide plus methylprednisolone in treatment of systemic rheumatoid vasculitis. Am J Med 76 : 377-384, 1984.
PubMed
7) Olive A, Riveros A, Juarez P, et al : Rheumatoid vasculitis : study of 41 cases. Med Clin (Barc) 155 : 126-129, 2020.
 
8) Pagnoux C, Mahr A, Cohen P, et al : Presentation and outcome of gastrointestinal involvement in systemic necrotizing vasculitides : analysis of 62 patients with polyarteritis nodosa, microscopic polyangiitis, Wegener granulomatosis, Churg-Strauss syndrome, or rheumatoid arthritis-associated vasculitis. Medicine (Baltimore) 84 : 115-128, 2005.
 
9) Turesson C, Jacobsson LT : Epidemiology of extra-articular manifestations in rheumatoid arthritis. Scand J Rheumatol 33 : 65-72, 2004.
 
10) Aletaha D, Neogi T, Silman AJ, et al : 2010 Rheumatoid arthritis classification criteria : an American College of Rheumatology/European League Against Rheumatism collaborative initiative. Arthritis Rheum 62 : 2569-2581, 2010.
 
11) Puechal X, Miceli-Richard C, Mejjad O, et al : Anti-tumour necrosis factor treatment in patients with refractory systemic vasculitis associated with rheumatoid arthritis. Ann Rheum Dis 67 : 880-884, 2008.
 
12) Ramos-Casals M, Roberto-Perez-Alvarez, Diaz-Lagares C, et al : Autoimmune diseases induced by biological agents : a double-edged sword? Autoimmun Rev 9 : 188-193, 2010.
 
13) Puechal X, Gottenberg JE, Berthelot JM, et al : Rituximab therapy for systemic vasculitis associated with rheumatoid arthritis : Results from the Autoimmunity and Rituximab Registry. Arthritis Care Res (Hoboken) 64 : 331-339, 2012.
 
P.334 掲載の参考文献
1) サルコイドーシス診療の手引き 2020 (日本サルコイドーシス/肉芽種性疾患学会サルコイドーシス診療の手引き作成委員会編), 2021. [https://www.jssog.com/wp/wp-content/themes/jssog/images/system/guidance/2-2-2.pdf]
 
2) Jennette JC, Falk RJ, Bacon PA, et al : 2012 revised International Chapel Hill Consensus Conference Nomenclature of Vasculitides. Arthritis Rheum 65 : 1-11, 2013.
 
3) Fernandes SR, Singsen BH, Hoffman GS : Sarcoidosis and systemic vasculitis. Semin Arthritis Rheum 30 : 33-46, 2000.
 
4) 陳科榮 : Sarcoid vasculitis. 最新医学 68 : 246-251, 2013.
 
5) 木谷匡志, 蛇澤品 : 肺肉芽腫性疾患の病理. 日本サルコイドーシス/肉芽腫性疾患学会雑誌 42 : 16-23, 2022.
 
6) Iannuzzi MC, Rybicki BA, Teirstein AS : Sarcoidosis. N Engl J Med 357 : 2153-2165, 2007.
 
7) Kawakami T, Soma Y : Successful use of mizoribine in a patient with sarcoidosis and cutaneous vasculitis. Acta Derm Venereol 91 : 582-583, 2011.
 
8) 日本皮膚科学血管炎・血管障害診療ガイドライン改訂版作成委員会 : 血管炎・血管障害診療ガイドライン 2016年改訂版. 日本皮膚科学会雑誌 127 : 299-415, 2017.
 
9) Baughman RP, Teirstein AS, Judson MA, et al : Clinical characteristics of patients in a case control study of sarcoidosis. Am J Respir Crit Care Med 164 : 1885-1889, 2001.
 
10) 日本神経治療学会 : 標準的神経治療 : 中枢神経の血管炎. 神経治療 34 : 554- 571, 2017.
 
11) 武村民子 : 病理から見たサルコイドーシスの鑑別診断. 日本サルコイドーシス/肉芽腫性疾患学会雑誌 36 : 45-51, 2016.
 
12) Maeda S, Murao S, Sugiyama T, et al : Generalized sarcoidosis with "sarcoid aortitis". Acta Pathol Jpn 33 : 183-188, 1983.
 
13) Lam CS, Tolep KA, Metke MP, et al : Coronary sarcoidosis presenting as acute coronary syndrome. Clin Cardiol 32 : E68-71, 2009.
 
14) Sweiss NJ, Patterson K, Sawaqed R, et al : Rheumatologic manifestations of sarcoidosis. Semin Respir Crit Care Med 31 : 463-473, 2010.
 
15) 神田浩子 : 全身疾患を伴う血管炎. 診断と治療 106 : 197-200, 2018.
 

書評

最近チェックした商品履歴

Loading...